SUSAN G KOMEN BREAST CANCER FOUNDATION: Form 990, tax year 2022

View the entire original 990 at ProPublica ↗

Organization: SUSAN G KOMEN BREAST CANCER FOUNDATION (EIN 75-1835298)
Tax period: 2022-04-01 to 2023-03-31
Filed: 2023-12-14
IRS object ID: 202323489349301342
Schema version: 2022v5.0
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2023-12-14T13:38:03+00:00	ReturnTs
Tax Period End	2023-03-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	346565596	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	ERNST & YOUNG US LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	1901 SIXTH AVENUE NORTH	AddressLine1Txt
City	BIRMINGHAM	CityNm
State Abbreviation	AL	StateAbbreviationCd
ZIP	35203	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2022-04-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	751835298	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	The Susan G Komen Breast Cancer Foundation Inc	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	SUSA	BusinessNameControlTxt
Phone	9728551600	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	13770 NOEL ROAD SUITE 801889	AddressLine1Txt
City	DALLAS	CityNm
State Abbreviation	TX	StateAbbreviationCd
ZIP	75380	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	PAULA SUE SCHNEIDER	PersonNm
Person Title	PRESIDENT AND CEO	PersonTitleTxt
Phone	9728551600	PhoneNum
Signature	2023-12-14	SignatureDt
Discuss With Paid Preparer	Yes (true)	DiscussWithPaidPreparerInd

Signing Officer SigningOfficerGrp

Person Full Name PersonFullName

Field	Value	IRS element (for citing)
Person First	PAULA	PersonFirstNm
Person Last	SCHNEIDER	PersonLastNm

Field	Value	IRS element (for citing)
SSN	999009999	SSN

Field	Value	IRS element (for citing)
IRS Responsible Prty Info Curr	Yes (true)	IRSResponsiblePrtyInfoCurrInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	Kathy Pitts	PreparerPersonNm
PTIN	P00292940	PTIN
Phone	2052512000	PhoneNum

Field	Value	IRS element (for citing)
Tax	2022	TaxYr
Build TS	2023-04-26 12:10:37Z	BuildTS

Form 990 IRS990

Doing Business As Name DoingBusinessAsName

Field	Value	IRS element (for citing)
Business Name Line1	SUSAN G KOMEN	BusinessNameLine1Txt

Principal Ofcr Business Name PrincipalOfcrBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	PAULA SUE SCHNEIDER	BusinessNameLine1Txt

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	13770 NOEL ROAD SUITE 801889	AddressLine1Txt
City	DALLAS	CityNm
State Abbreviation	TX	StateAbbreviationCd
ZIP	75380	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$118,544,114	GrossReceiptsAmt
Group Return For Affiliates	false	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.KOMEN.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1982	FormationYr
Legal Domicile State	TX	LegalDomicileStateCd
Activity Or Mission	OUR MISSION IS TO SAVE LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAK-THROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER.	ActivityOrMissionDesc
Voting Members Governing Body	19	VotingMembersGoverningBodyCnt
Voting Members Independent	19	VotingMembersIndependentCnt
Total Employee	468	TotalEmployeeCnt
Total Volunteers	7089	TotalVolunteersCnt
Total Gross UBI	$6,104	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$99,456,148	PYContributionsGrantsAmt
CY Contributions Grants	$111,805,407	CYContributionsGrantsAmt
PY Program Service Revenue	$2,500	PYProgramServiceRevenueAmt
CY Program Service Revenue	$0	CYProgramServiceRevenueAmt
PY Investment Income	$7,437,450	PYInvestmentIncomeAmt
CY Investment Income	$2,453,577	CYInvestmentIncomeAmt
PY Other Revenue	$4,365,358	PYOtherRevenueAmt
CY Other Revenue	-$6,661,279	CYOtherRevenueAmt
PY Total Revenue	$111,261,456	PYTotalRevenueAmt
CY Total Revenue	$107,597,705	CYTotalRevenueAmt
PY Grants And Similar Paid	$25,691,669	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$29,280,228	CYGrantsAndSimilarPaidAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$36,149,496	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$45,865,289	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$1,181,706	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$1,363,728	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$27,230,240	CYTotalFundraisingExpenseAmt
PY Other Expenses	$37,609,513	PYOtherExpensesAmt
CY Other Expenses	$40,554,624	CYOtherExpensesAmt
PY Total Expenses	$100,632,384	PYTotalExpensesAmt
CY Total Expenses	$117,063,869	CYTotalExpensesAmt
PY Revenues Less Expenses	$10,629,072	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$9,466,164	CYRevenuesLessExpensesAmt
Total Assets BOY	$207,354,061	TotalAssetsBOYAmt
Total Assets EOY	$192,631,082	TotalAssetsEOYAmt
Total Liabilities BOY	$59,717,916	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$62,957,218	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$147,636,145	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$129,673,864	NetAssetsOrFundBalancesEOYAmt
Mission	SUSAN G. KOMEN'S MISSION IS TO SAVE LIVES FROM BREAST CANCER BY FINDING BREAKTHROUGHS TO PREVENT, DETECT, TREAT, AND CURE BREAST CANCER, AND BY MEETING THE MOST CRITICAL NEEDS IN COMMUNITIES TO ENSURE EVERYONE GETS THE BREAST CANCER CARE THEY NEED WHEN THEY NEED IT.	MissionDesc
Significant New Program Srvc	false	SignificantNewProgramSrvcInd
Significant Change	false	SignificantChangeInd
Expense	$48,712,358	ExpenseAmt
Grant	$10,610,338	GrantAmt
Revenue	$0	RevenueAmt
Desc	PATIENT CARE: PROVISION OF BREAST CANCER SCREENING, DIAGNOSIS, AND TREATMENT PROGRAMS THROUGH GRANTS TO OTHER NON-PROFIT ORGANIZATIONS, THIRD-PARTY CONTRACTS AND DIRECTLY BY KOMEN, WITH SPECIAL EMPHASIS ON PATIENT NAVIGATION, ESPECIALLY IN COMMUNITIES WHERE DISPARITIES IN OUTCOMES ARE SIGNIFICANT AND/OR ACCESS IS LIMITED. SEE SCHEDULE O FOR ADDITIONAL DETAILS.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$24,634,101	ExpenseAmt
Grant	$18,669,890	GrantAmt
Revenue	$0	RevenueAmt
Desc	GRANTS TO RESEARCH INSTITUTIONS AND OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER RESEARCH PROJECTS INCLUDING THOSE FOCUSED ON THE BIOLOGY OF BREAST CANCER; NEW STRATEGIES TO TREAT, DETECT, AND PREDICT RISK OF BREAST CANCER, AND UNDERSTANDING AND ADDRESSING DISPARITIES IN OUTCOMES. SEE SCHEDULE O FOR ADDITIONAL DETAILS.	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$3,359,841	ExpenseAmt
Grant	$0	GrantAmt
Revenue	$0	RevenueAmt
Desc	PUBLIC POLICY AND ADVOCACY: INITIATIVES THAT HAVE THE POTENTIAL TO IMPACT ALL PEOPLE TOUCHED BY BREAST CANCER, INCLUDING ACTIVITIES ADVOCATING FOR LEGISLATIVE, REGULATORY AND OTHER POLICY SOLUTIONS DESIGNED TO SUPPORT KEY PATIENT PROTECTIONS, EXPAND ACCESS TO HIGH-QUALITY CARE, AND FUND CRITICAL BREAST CANCER RESEARCH. SEE SCHEDULE O FOR DETAILS.	Desc

Field	Value	IRS element (for citing)
Total Program Service Expenses	$76,706,300	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (true)	DescribedInSection501c3Ind
Schedule B Required	Yes (true)	ScheduleBRequiredInd
Political Campaign Acty	false	PoliticalCampaignActyInd
Lobbying Activities	Yes (true)	LobbyingActivitiesInd
Donor Advised Fund	false	DonorAdvisedFundInd
Conservation Easements	false	ConservationEasementsInd
Collections Of Art	false	CollectionsOfArtInd
Credit Counseling	false	CreditCounselingInd
Donor Rstr Or Quasi Endowments	Yes (true)	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (true)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	Yes (true)	ReportInvestmentsOtherSecInd
Report Program Related Invst	false	ReportProgramRelatedInvstInd
Report Other Assets	false	ReportOtherAssetsInd
Report Other Liabilities	false	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (true)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	false	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	Yes (true)	ConsolidatedAuditFinclStmtInd
School Operating	false	SchoolOperatingInd
Foreign Office	false	ForeignOfficeInd
Foreign Activities	Yes (true)	ForeignActivitiesInd
More Than5000 K To Org	Yes (true)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	false	MoreThan5000KToIndividualsInd
Professional Fundraising	Yes (true)	ProfessionalFundraisingInd
Fundraising Activities	Yes (true)	FundraisingActivitiesInd
Gaming Activities	false	GamingActivitiesInd
Operate Hospital	false	OperateHospitalInd
Grants To Organizations	Yes (true)	GrantsToOrganizationsInd
Grants To Individuals	Yes (true)	GrantsToIndividualsInd
Schedule J Required	Yes (true)	ScheduleJRequiredInd
Tax Exempt Bonds	false	TaxExemptBondsInd
Engaged In Excess Benefit Trans	false	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	false	PYExcessBenefitTransInd
Loan Outstanding	false	LoanOutstandingInd
Grant To Related Person	false	GrantToRelatedPersonInd
Business Rln With Org Mem	false	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	false	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	false	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	Yes (true)	DeductibleNonCashContriInd
Deductible Art Contribution	false	DeductibleArtContributionInd
Terminate Operations	false	TerminateOperationsInd
Partial Liquidation	false	PartialLiquidationInd
Disregarded Entity	false	DisregardedEntityInd
Related Entity	false	RelatedEntityInd
Related Organization Ctrl Ent	false	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	false	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	false	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (true)	ScheduleORequiredInd
IRP Document	193	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (true)	BackupWthldComplianceInd
Employee	468	EmployeeCnt
Employment Tax Returns Filed	Yes (true)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	Yes (true)	UnrelatedBusIncmOverLimitInd
Form990 T Filed	Yes (true)	Form990TFiledInd
Foreign Financial Account	false	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTransInd
Taxable Party Notification	false	TaxablePartyNotificationInd
Nondeductible Contributions	false	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (true)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (true)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	Yes (true)	Form8282PropertyDisposedOfInd
Form8282 Filed	2	Form8282FiledCnt
Rcv Fnds To Pay Prsnl Bnft Cntrct	false	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	false	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	false	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	false	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	false	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	19	GoverningBodyVotingMembersCnt
Independent Voting Member	19	IndependentVotingMemberCnt
Family Or Business Rln	false	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	false	DelegationOfMgmtDutiesInd
Change To Org Documents	false	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	false	MaterialDiversionOrMisuseInd
Members Or Stockholders	false	MembersOrStockholdersInd
Election Of Board Members	false	ElectionOfBoardMembersInd
Decisions Subject To Approva	false	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (true)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (true)	MinutesOfCommitteesInd
Officer Mailing Address	false	OfficerMailingAddressInd
Local Chapters	Yes (true)	LocalChaptersInd
Policies Reference Chapters	Yes (true)	PoliciesReferenceChaptersInd
Form990 Provided To Gvrn Body	Yes (true)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (true)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (true)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (true)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (true)	WhistleblowerPolicyInd
Document Retention Policy	Yes (true)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (true)	CompensationProcessCEOInd
Compensation Process Other	Yes (true)	CompensationProcessOtherInd
Investment In Joint Venture	false	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	DC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	LA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ME	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ND	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AZ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RIA WILLIAMS	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	9728551600	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	13770 NOEL ROAD SUITE 801889	AddressLine1Txt
City	DALLAS	CityNm
State Abbreviation	TX	StateAbbreviationCd
ZIP	75380	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (33 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd	Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd
Ed Dandridge
Chair of the Board	1.0	0	Yes (X)	Yes (X)	$0	$0	$0
Jerri Johnson
BOD MEMBER (VICE CHAIR)	1.0	0	Yes (X)	Yes (X)	$0	$0	$0
Andi Owen
BOD Member (ending March 2023)	1.0	0	Yes (X)		$0	$0	$0
BJ Schaknowski
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Boris Dolgonos
BOD Member (beginning March 2023)	1.0	0	Yes (X)		$0	$0	$0
Christina Minnis
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Gail Heimann
BOD Member	1.0	0	Yes (X)		$0	$0	$0
John O'Neill
BOD Member (ended April 2022)	1.0	0	Yes (X)		$0	$0	$0
Julia Harris
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Julie Gruber
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Kristen Racich
BOD Member	1.0	0	Yes (X)		$0	$0	$0
LaQuenta Jacobs
BOD Member (beginning March 2023)	1.0	0	Yes (X)		$0	$0	$0
Luke Sauter
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Lydia The
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Michelle Bottomley
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Peter Brundage
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Renee Baker
BOAD Member	1.0	0	Yes (X)		$0	$0	$0
Robyn Shepherd
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Sean Slovenski
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Traci Blunt
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Valerie Rainey
BOD Member (beginning March 2023)	1.0	0	Yes (X)		$0	$0	$0
Eunice Nakamura
General Counsel and Corporate Secretary	55.0	0		Yes (X)	$273,878	$0	$23,687
Paula Schneider
President and CEO	55.0	0		Yes (X)	$888,164	$0	$27,615
Ria Williams
Chief Fin & Ops Officer	55.0	0		Yes (X)	$319,076	$0	$30,635
Catherine Olivieri
SVP, Human Resources	55.0	0			$277,075	$0	$26,419	Yes (X)
Lori Maris
SVP, OPS SERVICES & SUPPORT	55.0	0			$240,233	$0	$15,349	Yes (X)
Victoria Smart
SVP, Mission	55.0	0			$331,477	$0	$15,705	Yes (X)
Catherine Stone
VP, Community Health	55.0	0			$213,060	$0	$13,131		Yes (X)
Kari Bodell
VP, Development Programs Strategy	55.0	0			$239,625	$0	$14,169		Yes (X)
Michelle Strong
VP, Marketing Strategy	55.0	0			$233,180	$0	$22,360		Yes (X)
Sarah Rosales
VP, Corporate Partnerships	55.0	0			$257,358	$0	$29,351		Yes (X)
Srinivasu Avadhanula
VP, BI Platform & Engineering	55.0	0			$249,792	$0	$23,614		Yes (X)
Dana Brown
Chief Operating Officer (Term 3/31/22)	0.0	0			$184,757	$0	$5,580			Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$3,707,675	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$247,615	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	116	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	false	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (true)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	false	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt	Address Line2ContractorAddress/USAddress/AddressLine2Txt
Event 360
205 N Michigan Ave	Chicago	IL	60601	Event Management	$3,132,937
RKD Group LLC
3400 Waterview Parkway	Richardson	TX	75080	Consulting	$1,014,986
Prometheus Research LLC
One Audubon Street	New Haven	CT	06511	Technology Services	$460,000	4th Fllor
MSB Financial Solutions LLC
79 Cherrywood Dr	Nashua	NH	03062	Software Services	$445,942
Ernst & Young
3712 Solutions Center	Chicago	IL	60677	Acctg & Tax Services	$342,243

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	17	CntrctRcvdGreaterThan100KCnt
Federated Campaigns	$432,565	FederatedCampaignsAmt
Membership Dues	$0	MembershipDuesAmt
Fundraising	$35,668,334	FundraisingAmt
Related Organizations	$0	RelatedOrganizationsAmt
Government Grants	$0	GovernmentGrantsAmt
All Other Contributions	$75,704,508	AllOtherContributionsAmt
Noncash Contributions	$592,477	NoncashContributionsAmt
Total Contributions	$111,805,407	TotalContributionsAmt

Total Oth Program Service Rev TotalOthProgramServiceRevGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Field	Value	IRS element (for citing)
Total Program Service Revenue	$0	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$1,438,781	TotalRevenueColumnAmt
Exclusion	$1,438,781	ExclusionAmt

Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Exclusion	$0	ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Exclusion	$0	ExclusionAmt

Gross Rents GrossRentsGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Less Rental Expenses LessRentalExpensesGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$3,316,237	SecuritiesAmt
Other	$0	OtherAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$2,301,441	SecuritiesAmt
Other	$0	OtherAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$1,014,796	SecuritiesAmt
Other	$0	OtherAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$1,014,796	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$1,014,796	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$1,820,234	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$35,668,334	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$8,533,874	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$6,713,640	TotalRevenueColumnAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	-$6,713,640	ExclusionAmt

Field	Value	IRS element (for citing)
Gaming Gross Income	$29,627	GamingGrossIncomeAmt
Gaming Direct Expenses	$45,162	GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$15,535	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	-$15,535	ExclusionAmt

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	$107,070	GrossSalesOfInventoryAmt
Cost Of Goods Sold	$65,932	CostOfGoodsSoldAmt

Net Income Or Loss NetIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$41,138	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$41,138	ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp (3 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt	Unrelated Business RevenueUnrelatedBusinessRevenueAmt	ExclusionExclusionAmt
OTHER INCOME	900099	$26,758	$0	$6,104	$20,654
		$0	$0	$0	$0
		$0	$0	$0	$0

Miscellaneous Revenue MiscellaneousRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Field	Value	IRS element (for citing)
Other Revenue Total	$26,758	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$107,597,705	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$6,104	UnrelatedBusinessRevenueAmt
Exclusion	-$4,213,806	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$19,635,695	TotalAmt
Program Services	$19,635,695	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$9,078,750	TotalAmt
Program Services	$9,078,750	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$565,783	TotalAmt
Program Services	$565,783	ProgramServicesAmt

Benefits To Members BenefitsToMembersGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$2,482,405	TotalAmt
Program Services	$1,282,179	ProgramServicesAmt
Management And General	$538,632	ManagementAndGeneralAmt
Fundraising	$661,594	FundraisingAmt

Comp Disqual Persons CompDisqualPersonsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$36,277,286	TotalAmt
Program Services	$18,726,067	ProgramServicesAmt
Management And General	$7,828,981	ManagementAndGeneralAmt
Fundraising	$9,722,238	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$1,479,554	TotalAmt
Program Services	$779,973	ProgramServicesAmt
Management And General	$303,129	ManagementAndGeneralAmt
Fundraising	$396,452	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$3,014,565	TotalAmt
Program Services	$1,502,541	ProgramServicesAmt
Management And General	$748,043	ManagementAndGeneralAmt
Fundraising	$763,981	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$2,611,479	TotalAmt
Program Services	$1,337,671	ProgramServicesAmt
Management And General	$560,570	ManagementAndGeneralAmt
Fundraising	$713,238	FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$150,411	TotalAmt
Program Services	$60,819	ProgramServicesAmt
Management And General	$29,864	ManagementAndGeneralAmt
Fundraising	$59,728	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$342,030	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$342,030	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$293,520	TotalAmt
Program Services	$293,520	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$1,363,728	TotalAmt
Fundraising	$1,363,728	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$5,738,163	TotalAmt
Program Services	$3,331,081	ProgramServicesAmt
Management And General	$198,565	ManagementAndGeneralAmt
Fundraising	$2,208,517	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$16,194,959	TotalAmt
Program Services	$8,190,560	ProgramServicesAmt
Management And General	$162,466	ManagementAndGeneralAmt
Fundraising	$7,841,933	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$2,065,603	TotalAmt
Program Services	$846,897	ProgramServicesAmt
Management And General	$619,681	ManagementAndGeneralAmt
Fundraising	$599,025	FundraisingAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$174,523	TotalAmt
Program Services	$107,985	ProgramServicesAmt
Management And General	$29,887	ManagementAndGeneralAmt
Fundraising	$36,651	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$1,194,739	TotalAmt
Program Services	$589,628	ProgramServicesAmt
Management And General	$341,009	ManagementAndGeneralAmt
Fundraising	$264,102	FundraisingAmt

Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$224,153	TotalAmt
Program Services	$97,027	ProgramServicesAmt
Management And General	$95,686	ManagementAndGeneralAmt
Fundraising	$31,440	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Payments To Affiliates PaymentsToAffiliatesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$1,162,453	TotalAmt
Program Services	$904,513	ProgramServicesAmt
Management And General	$135,072	ManagementAndGeneralAmt
Fundraising	$122,868	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$499,600	TotalAmt
Program Services	$499,600	ProgramServicesAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
CONSULT & PROF. FEES	$6,582,084	$5,401,593	$389,052	$791,439
EQUIP RENTAL & MAINT	$3,127,554	$2,008,073	$401,706	$717,775
MERCHANT SERVICES & BANK FEES	$1,765,647	$1,022,682	$105,221	$637,744
EVENT PRODUCTION	$235,470	$113,585	$14,066	$107,819

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$803,715	TotalAmt
Program Services	$330,078	ProgramServicesAmt
Management And General	$283,669	ManagementAndGeneralAmt
Fundraising	$189,968	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$117,063,869	TotalAmt
Program Services	$76,706,300	ProgramServicesAmt
Management And General	$13,127,329	ManagementAndGeneralAmt
Fundraising	$27,230,240	FundraisingAmt

Total Joint Costs TotalJointCostsGrp

Field	Value	IRS element (for citing)
Total	$48,508,025	TotalAmt
Program Services	$24,374,495	ProgramServicesAmt
Management And General	$1,206,569	ManagementAndGeneralAmt
Fundraising	$22,926,961	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$23,067,395	BOYAmt
EOY	$11,205,049	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$15,045,253	BOYAmt
EOY	$15,405,966	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$9,577	BOYAmt
EOY	$47,380	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$2,120,424	BOYAmt
EOY	$1,613,365	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$13,932,941	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$9,579,406	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$3,645,471	BOYAmt
EOY	$4,353,535	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$119,988,473	BOYAmt
EOY	$114,281,787	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$43,470,000	BOYAmt
EOY	$43,470,000	EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt

Intangible Assets IntangibleAssetsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$7,468	BOYAmt
EOY	$2,254,000	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$207,354,061	BOYAmt
EOY	$192,631,082	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$9,791,057	BOYAmt
EOY	$9,306,708	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$49,697,151	BOYAmt
EOY	$53,366,811	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$229,708	BOYAmt
EOY	$283,699	EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$59,717,916	BOYAmt
EOY	$62,957,218	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$98,403,421	BOYAmt
EOY	$84,243,927	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$49,232,724	BOYAmt
EOY	$45,429,937	EOYAmt

Cap Stk Tr Prin Current Funds CapStkTrPrinCurrentFundsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Pd In Cap Srpls Land Bldg Eqp Fund PdInCapSrplsLandBldgEqpFundGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Rtn Earn Endowment Incm Oth Fnds RtnEarnEndowmentIncmOthFndsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$147,636,145	BOYAmt
EOY	$129,673,864	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$207,354,061	BOYAmt
EOY	$192,631,082	EOYAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	Yes (X)	InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss	-$9,466,164	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	-$11,884,802	NetUnrlzdGainsLossesInvstAmt
Donated Services And Use Fclts	-$63,954	DonatedServicesAndUseFcltsAmt
Investment Expense	-$316,359	InvestmentExpenseAmt
Prior Period Adjustments	$0	PriorPeriodAdjustmentsAmt
Other Changes In Net Assets	$1,068,998	OtherChangesInNetAssetsAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	false	AccountantCompileOrReviewInd
FS Audited	Yes (true)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Consolidated Basis Fincl Stmt	Yes (X)	ConsolidatedBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (true)	AuditCommitteeInd
Federal Grant Audit Required	false	FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$63,291,987	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$59,972,314	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$50,983,746	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$99,456,148	CurrentTaxYearMinus1YearAmt
Current Tax Year	$111,805,407	CurrentTaxYearAmt
Total	$385,509,602	TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$63,291,987	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$59,972,314	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$50,983,746	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$99,456,148	CurrentTaxYearMinus1YearAmt
Current Tax Year	$111,805,407	CurrentTaxYearAmt
Total	$385,509,602	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$19,028,970	SubstantialContributorsTotAmt
Public Support Total170	$366,480,632	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$5,221,701	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$4,928,838	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$1,217,543	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$1,156,360	CurrentTaxYearMinus1YearAmt
Current Tax Year	$1,438,781	CurrentTaxYearAmt
Total	$13,963,223	TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$34,200	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$86,442	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$15,070	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$3,574	CurrentTaxYearMinus1YearAmt
Current Tax Year	$26,758	CurrentTaxYearAmt
Total	$166,044	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$399,638,869	TotalSupportAmt
Gross Receipts Rltd Activities	$65,072,779	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.9170	PublicSupportCY170Pct
Public Support PY170	0.8199	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule A, Part II, Line 10 Other Income	FormAndLineReferenceDesc
Explanation	DESCRIPTION - OTHER INCOME, COLUMN A - 34200.0, COLUMN B - 86442.0, COLUMN C - 15070.0, COLUMN D - 3574.0, COLUMN E - 26758.0, COLUMN F - 166044.0;	ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Total Grassroots Lobbying TotalGrassrootsLobbyingGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$15,803	FilingOrganizationsTotalAmt
Affiliated Group Total	$15,803	AffiliatedGroupTotalAmt

Total Direct Lobbying TotalDirectLobbyingGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$277,717	FilingOrganizationsTotalAmt
Affiliated Group Total	$277,717	AffiliatedGroupTotalAmt

Total Lobbying Expend TotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$293,520	FilingOrganizationsTotalAmt
Affiliated Group Total	$293,520	AffiliatedGroupTotalAmt

Other Exempt Purpose Expend OtherExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$103,643,020	FilingOrganizationsTotalAmt
Affiliated Group Total	$103,669,862	AffiliatedGroupTotalAmt

Total Exempt Purpose Expend TotalExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$103,936,540	FilingOrganizationsTotalAmt
Affiliated Group Total	$103,963,382	AffiliatedGroupTotalAmt

Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$1,000,000	FilingOrganizationsTotalAmt
Affiliated Group Total	$1,000,000	AffiliatedGroupTotalAmt

Grassroots Nontaxable GrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$250,000	FilingOrganizationsTotalAmt
Affiliated Group Total	$250,000	AffiliatedGroupTotalAmt

Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt
Affiliated Group Total	$0	AffiliatedGroupTotalAmt

Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt
Affiliated Group Total	$0	AffiliatedGroupTotalAmt

Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$1,000,000	CurrentYearMinus3Amt
Current Year Minus2	$1,000,000	CurrentYearMinus2Amt
Current Year Minus1	$1,000,000	CurrentYearMinus1Amt
Current Year	$1,000,000	CurrentYearAmt
Total	$4,000,000	TotalAmt

Field	Value	IRS element (for citing)
Lobbying Ceiling	$6,000,000	LobbyingCeilingAmt

Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$343,462	CurrentYearMinus3Amt
Current Year Minus2	$172,474	CurrentYearMinus2Amt
Current Year Minus1	$204,997	CurrentYearMinus1Amt
Current Year	$293,520	CurrentYearAmt
Total	$1,014,453	TotalAmt

Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$250,000	CurrentYearMinus3Amt
Current Year Minus2	$250,000	CurrentYearMinus2Amt
Current Year Minus1	$250,000	CurrentYearMinus1Amt
Current Year	$250,000	CurrentYearAmt
Total	$1,000,000	TotalAmt

Field	Value	IRS element (for citing)
Grassroots Ceiling	$1,500,000	GrassrootsCeilingAmt

Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$86,368	CurrentYearMinus3Amt
Current Year Minus2	$386,160	CurrentYearMinus2Amt
Current Year Minus1	$26,906	CurrentYearMinus1Amt
Current Year	$15,803	CurrentYearAmt
Total	$515,237	TotalAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule C, Part II-A Lobbying Expenses	FormAndLineReferenceDesc
Explanation	PUBLIC POLICY AND ADVOCACY INITIATIVES HAVE THE POTENTIAL TO IMPACT ALL PEOPLE TOUCHED BY BREAST CANCER. RECOGNIZING THE IMPORTANCE OF THIS WORK TO ACCOMPLISH ITS MISSION, KOMEN SUPPORTS LIMITED LOBBYING ACTIVITIES TO ACHIEVE LEGISLATIVE AND REGULATORY SOLUTIONS DESIGNED TO SUPPORT KEY PATIENT PROTECTIONS, EXPAND ACCESS TO HIGH-QUALITY CARE AND FUND CRITICAL BREAST CANCER RESEARCH.	ExplanationTxt

Schedule D IRS990ScheduleD

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,346,868	BeginningYearBalanceAmt
Contributions	$2,279,000	ContributionsAmt
Investment Earnings Or Losses	-$7,607	InvestmentEarningsOrLossesAmt
Other Expenditures	$5,713	OtherExpendituresAmt
End Year Balance	$3,612,548	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,342,173	BeginningYearBalanceAmt
Contributions	$0	ContributionsAmt
Investment Earnings Or Losses	$10,613	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$5,918	OtherExpendituresAmt
Administrative Expenses	$0	AdministrativeExpensesAmt
End Year Balance	$1,346,868	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,337,562	BeginningYearBalanceAmt
Contributions	$0	ContributionsAmt
Investment Earnings Or Losses	$10,279	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$5,668	OtherExpendituresAmt
Administrative Expenses	$0	AdministrativeExpensesAmt
End Year Balance	$1,342,173	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,333,603	BeginningYearBalanceAmt
Contributions	$0	ContributionsAmt
Investment Earnings Or Losses	$9,803	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$5,844	OtherExpendituresAmt
Administrative Expenses	$0	AdministrativeExpensesAmt
End Year Balance	$1,337,562	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,362,090	BeginningYearBalanceAmt
Contributions	$0	ContributionsAmt
Investment Earnings Or Losses	-$4,016	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$24,267	OtherExpendituresAmt
Administrative Expenses	$204	AdministrativeExpensesAmt
End Year Balance	$1,333,603	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Board Designated Balance EOY	0.277	BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY	0.721	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.002	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	false	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	false	EndowmentsHeldRelatedOrgInd

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$2,357,161	OtherCostOrOtherBasisAmt
Depreciation	$1,967,638	DepreciationAmt
Book Value	$389,523	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$11,575,780	OtherCostOrOtherBasisAmt
Depreciation	$7,611,768	DepreciationAmt
Book Value	$3,964,012	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$4,353,535	TotalBookValueLandBuildingsAmt

Other Securities OtherSecuritiesGrp

Field	Value	IRS element (for citing)
Desc	PRIVATE EQUITY FUND	Desc
Book Value	$43,470,000	BookValueAmt
Method Valuation	F	MethodValuationCd

Field	Value	IRS element (for citing)
Total Book Value Securities	$43,470,000	TotalBookValueSecuritiesAmt
Total Liability	$0	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$127,818,234	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	-$11,884,802	NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts	$32,764,307	DonatedServicesAndUseFcltsAmt
Other Revenue	-$342,617	OtherRevenueAmt
Revenue Not Reported	$20,536,888	RevenueNotReportedAmt
Revenue Subtotal	$107,281,346	RevenueSubtotalAmt
Investment Expenses Not Incld	$316,359	InvestmentExpensesNotIncldAmt
Other Revenues Not Included	$0	OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt	$316,359	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$107,597,705	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$148,480,516	TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts	$32,485,644	DonatedServicesUseFcltsAmt
Other Expenses Included	-$1,068,997	OtherExpensesIncludedAmt
Expenses Not Reported	$31,416,647	ExpensesNotReportedAmt
Expenses Subtotal	$117,063,869	ExpensesSubtotalAmt
Other Expenses Not Included	$0	OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt	$0	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$117,063,869	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (4 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Schedule D, Part V, Line 4 Intended uses of endowment funds	KOMEN HAS FIVE PERMANENT ENDOWMENTS: GOODMAN-BRINKER, FIRNBERG, TWO GENERAL ENDOWMENTS, AND A PERPETUAL TRUST. THE GOODMAN-BRINKER ENDOWMENT IS FOR BREAST CANCER RESEARCH FELLOWSHIPS, THE FIRNBERG ENDOWMENT IS FOR BREAST CANCER EDUCATIONAL PROGRAMS AND RESEARCH AWARDS, THE GENERAL ENDOWMENT AND PERPETUAL TRUST'S EARNINGS ARE RESTRICTED FOR ORGANIZATIONAL MISSION ACTIVITIES.
Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote	THE ORGANIZATION IS SUBJECT TO A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE WERE NO UNCERTAIN TAX POSITIONS RECORDED IN THE CONSOLIDATED FINANCIAL STATEMENTS AT MARCH 31, 2023
Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990	In Kind Services Direct Costs - -342617
Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990	Rescinded Grants - -1101560 Program Cost of Goods Sold - 32563

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (14 entries)

RegionRegionTxt	EmployeeEmployeeCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
East Asia and the Pacific	1	Grantmaking	Research	$31,483
Europe (Including Iceland and Greenland)	1	Fundraising	Fundraising Support	$21,940
Europe (Including Iceland and Greenland)	4	Grantmaking	Research	$238,914
Europe (Including Iceland and Greenland)	1	Program Services	Learning Mgmt System	$15,007
Europe (Including Iceland and Greenland)	1	Program Services	Mission Tool Development	$30,375
Europe (Including Iceland and Greenland)	1	Program Services	Professional Membership	$3,250
North America (Canada & Mexico only)	3	Grantmaking	Research	$295,386
North America (Canada & Mexico only)	1	Program Services	Mission Support	$68,946
North America (Canada & Mexico only)	1	Program Services	Mission Tool Development	$33,308
North America (Canada & Mexico only)	1	Program Services	Professional Membership	$18,000
North America (Canada & Mexico only)	1	Program Services	Software Licenses	$24,261
North America (Canada & Mexico only)	1	Program Services	Research	$1,000
North America (Canada & Mexico only)	1	Public Relations	Public Relations	$8,141
Europe (Including Iceland and Greenland)	1	Program Services	Sponsorship of Mission Programs	$102,500

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	19	SubtotalEmployeesCnt
Continuation Total Office	0	ContinuationTotalOfficeCnt
Continuation Total Employee	0	ContinuationTotalEmployeeCnt
Total Office	0	TotalOfficeCnt
Total Employee	19	TotalEmployeeCnt
Subtotal Spent	$892,511	SubtotalSpentAmt
Continuation Spent	$0	ContinuationSpentAmt
Total Spent	$892,511	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (7 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt
East Asia and the Pacific	Research	$31,483
East Asia and the Pacific	Research	$74,544
North America (Canada & Mexico only)	Research	$74,544
North America (Canada & Mexico only)	Research	$89,827
North America (Canada & Mexico only)	Research	$145,385
Europe (Including Iceland and Greenland)	Research	$75,000
Europe (Including Iceland and Greenland)	Research	$75,000

Field	Value	IRS element (for citing)
Total501c3 Org	5	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt
Transfer To Foreign Corp	Yes (true)	TransferToForeignCorpInd
Interest In Foreign Trust	false	InterestInForeignTrustInd
Foreign Corp Ownership	Yes (true)	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	false	PassiveForeignInvestmestCoInd
Foreign Partnership	false	ForeignPartnershipInd
Boycott Countries	false	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Schedule F, Part I, Line 2 Procedures for monitoring use of grant funds	AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, ALL GRANTEES ARE REQUIRED TO SUBMIT SCIENTIFIC PROGRESS REPORTS AND FINANCIAL REPORTS IN THE FORMAT REQUIRED BY KOMEN AND IN ACCORDANCE WITH THE SCHEDULE SET FORTH IN THE POLICIES AND ANY CHANGE REQUESTS THEY MAY HAVE FOR THEIR PROJECTS. ALL PROGRESS REPORTS AND REQUESTS ARE REVIEWED BY QUALIFIED STAFF. SEE SCHEDULE I, PART IV AND SCHEDULE O, Part IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS.
Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements	EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual
Schedule F, Part II, Line 1 Method used to account for expenditures on org's financial statements	EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	Yes (X)	MailSolicitationsInd
Email Solicitations	Yes (X)	EmailSolicitationsInd
Phone Solicitations	Yes (X)	PhoneSolicitationsInd
In Person Solicitations	Yes (X)	InPersonSolicitationsInd
Solicitation Of Non Govt Grants	Yes (X)	SolicitationOfNonGovtGrantsInd
Special Fundraising Events	Yes (X)	SpecialFundraisingEventsInd
Agrmt Prof Fundraising Acty	Yes (true)	AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (4 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	ActivityActivityTxt	Fundraiser Control Of FundsFundraiserControlOfFundsInd	Gross ReceiptsGrossReceiptsAmt	Retained By ContractorRetainedByContractorAmt	Net To OrganizationNetToOrganizationAmt
Event 360
55 E Jackson Blvd Suite 1010	Chicago	IL	60604	Fundraising Consultant	false	$14,471,684	$783,234	$13,688,450
Revunami Inc
228 E 85th St Suite 9C	New York	NY	10028	Marketing Consultant	false		$14,061	-$14,061
RKD Group LLC
3400 Waterview Parkway Suite 250	Richardson	TX	75080	Fundraising Consultant	false	$24,004,781	$533,010	$23,471,771
InKind Inc DBA GoodUnited
796 Meeting STreet	Charleston	SC	29403	Fundraising Consulting	false	$1,484,191	$33,423	$1,450,768

Field	Value	IRS element (for citing)
Total Gross Receipts	$39,960,656	TotalGrossReceiptsAmt
Total Retained By Contractors	$1,363,728	TotalRetainedByContractorsAmt
Total Net To Organization	$38,596,928	TotalNetToOrganizationAmt
Licensed States	CA	LicensedStatesCd
Licensed States	CO	LicensedStatesCd
Licensed States	CT	LicensedStatesCd
Licensed States	DC	LicensedStatesCd
Licensed States	FL	LicensedStatesCd
Licensed States	GA	LicensedStatesCd
Licensed States	AL	LicensedStatesCd
Licensed States	HI	LicensedStatesCd
Licensed States	ID	LicensedStatesCd
Licensed States	IL	LicensedStatesCd
Licensed States	IN	LicensedStatesCd
Licensed States	IA	LicensedStatesCd
Licensed States	KS	LicensedStatesCd
Licensed States	KY	LicensedStatesCd
Licensed States	LA	LicensedStatesCd
Licensed States	ME	LicensedStatesCd
Licensed States	AK	LicensedStatesCd
Licensed States	MD	LicensedStatesCd
Licensed States	MA	LicensedStatesCd
Licensed States	MI	LicensedStatesCd
Licensed States	MN	LicensedStatesCd
Licensed States	MS	LicensedStatesCd
Licensed States	MO	LicensedStatesCd
Licensed States	MT	LicensedStatesCd
Licensed States	NE	LicensedStatesCd
Licensed States	NV	LicensedStatesCd
Licensed States	NH	LicensedStatesCd
Licensed States	NJ	LicensedStatesCd
Licensed States	NM	LicensedStatesCd
Licensed States	NY	LicensedStatesCd
Licensed States	NC	LicensedStatesCd
Licensed States	ND	LicensedStatesCd
Licensed States	OH	LicensedStatesCd
Licensed States	OK	LicensedStatesCd
Licensed States	OR	LicensedStatesCd
Licensed States	PA	LicensedStatesCd
Licensed States	AZ	LicensedStatesCd
Licensed States	RI	LicensedStatesCd
Licensed States	SC	LicensedStatesCd
Licensed States	SD	LicensedStatesCd
Licensed States	TN	LicensedStatesCd
Licensed States	TX	LicensedStatesCd
Licensed States	UT	LicensedStatesCd
Licensed States	VT	LicensedStatesCd
Licensed States	VA	LicensedStatesCd
Licensed States	AR	LicensedStatesCd
Licensed States	WA	LicensedStatesCd
Licensed States	WV	LicensedStatesCd
Licensed States	WI	LicensedStatesCd
Licensed States	WY	LicensedStatesCd

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	3 Day Series	Event1Nm
Gross Receipts Event1	$14,385,465	GrossReceiptsEvent1Amt
Charitable Contri Event1	$14,171,508	CharitableContriEvent1Amt
Gross Revenue Event1	$213,957	GrossRevenueEvent1Amt
Cash Prizes Event1	$0	CashPrizesEvent1Amt
Non Cash Prizes Event1	$15,601	NonCashPrizesEvent1Amt
Rent Facility Costs Event1	$2,020,744	RentFacilityCostsEvent1Amt
Food And Beverage Event1	$475,001	FoodAndBeverageEvent1Amt
Entertainment Event1	$0	EntertainmentEvent1Amt
Other Direct Expenses Event1	$1,351,776	OtherDirectExpensesEvent1Amt
Event2	Race-Walk Events	Event2Nm
Gross Receipts Event2	$20,377,979	GrossReceiptsEvent2Amt
Charitable Contri Event2	$19,569,955	CharitableContriEvent2Amt
Gross Revenue Event2	$808,024	GrossRevenueEvent2Amt
Cash Prizes Event2	$0	CashPrizesEvent2Amt
Non Cash Prizes Event2	$731,448	NonCashPrizesEvent2Amt
Rent Facility Costs Event2	$263,961	RentFacilityCostsEvent2Amt
Food And Beverage Event2	$264,485	FoodAndBeverageEvent2Amt
Entertainment Event2	$18,952	EntertainmentEvent2Amt
Other Direct Expenses Event2	$2,643,606	OtherDirectExpensesEvent2Amt
Other Events Total	50	OtherEventsTotalCnt
Gross Receipts Other Events	$2,725,124	GrossReceiptsOtherEventsAmt
Charitable Contri Other Events	$1,926,871	CharitableContriOtherEventsAmt
Gross Revenue Other Events	$798,253	GrossRevenueOtherEventsAmt
Cash Prizes Other Events	$0	CashPrizesOtherEventsAmt
Non Cash Prizes Other Events	$21,957	NonCashPrizesOtherEventsAmt
Rent Fclty Costs Other Events	$190,649	RentFcltyCostsOtherEventsAmt
Food And Beverage Other Events	$325,855	FoodAndBeverageOtherEventsAmt
Entertainment Other Events	$26,300	EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events	$183,539	OthDirectExpnssOtherEventsAmt
Gross Receipts Total	$37,488,568	GrossReceiptsTotalAmt
Charitable Contributions Tot	$35,668,334	CharitableContributionsTotAmt
Gross Revenue Total Events	$1,820,234	GrossRevenueTotalEventsAmt
Cash Prizes Total Events	$0	CashPrizesTotalEventsAmt
Non Cash Prizes Total Events	$769,006	NonCashPrizesTotalEventsAmt
Rent Fclty Costs Total Events	$2,475,354	RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events	$1,065,341	FoodAndBeverageTotalEventsAmt
Entertainment Total Events	$45,252	EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events	$4,178,921	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$8,533,874	DirectExpenseSummaryEventsAmt
Net Income Summary	-$6,713,640	NetIncomeSummaryAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule G, Part II Net Income Summary	FormAndLineReferenceDesc
Explanation	Gross receipts are reduced by the amount of fundraising contributions, per IRS instructions. The contributions for fiscal year 2023 were $35,668,334.	ExplanationTxt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (65 entries)

Recipient EINRecipientEIN	Cash GrantCashGrantAmt	Purpose Of GrantPurposeOfGrantTxt
Alliance for Clinical Trials in Oncology
020464400	$103,344	Research
AMITA Health
362235165	$12,600	Patient Care
Barnes-Jewish Hospital
237309937	$37,500	Patient Care
Baylor College Medicine
741613878	$347,799	Research
Baylor University
741159753	$330,000	Research
Board of Regents of the University of
731563627	$57,504	Research
Boston University
042103547	$199,448	Research
Brigham and Women's Hospital
042312909	$36,000	Research
Burnham Institute for Medical Research
510197108	$49,994	Research
Cedars Sinai Medical Center
951644600	$115,337	Research
Columbia University Medical Center
135598093	$386,422	Research
Dana Farber Cancer Institute
042263040	$892,588	Research
Dana-Farber Cancer Institute Inc
042263040	$392,380	Research
Duke University Medical Center
560532129	$546,914	Research
Eastern Michigan University
382953297	$87,500	Education
ECOG Research and Education Foundation
391723095	$101,486	Research
Emory University
580566256	$189,917	Research
Georgetown University
522339873	$5,815	Research
Harvard Medical School
042103580	$100,000	Research
Indiana University (Indianapolis)
356001673	$809,308	Research
Johns Hopkins University
520595110	$312,500	Research
Johns Hopkins University
520595110	$75,000	Research
Lake County Health Department
593502843	$5,105	Patient Care
Leland Stanford Jr University
941156365	$300,000	Research
Loyola University Chicago
361408475	$165,000	Research
Mayo Clinic Jacksonville
593337028	$220,000	Research
McDonough County Health Department
376001537	$4,419	Patient Care
Memorial Sloan-Kettering Cancer Ctr
131924236	$374,999	Research
Mount Sinai School of Medicine
136171197	$134,750	Research
Oregon Health & Science University
752668014	$429,396	Research
Parkland Foundation
752089180	$100,000	Patient Care
Presence Hospitals PRV
344195126	$6,300	Patient Care
Princeton University
210634501	$300,000	Research
Roswell Park Alliance Foundation
161391608	$75,000	Research
Rush University Medical Center
362174823	$220,000	Research
Stanford University
941156365	$375,137	Research
SUNY at Stony Brook
141368361	$33,783	Research
The Ohio State University College
316025986	$67,500	Research
The Salk Institute
952160097	$75,000	Research
The University of Chicago
362177139	$67,500	Research
The University of Toledo
346401483	$57,190	Research
Touchette Regional Hospital Inc
371305510	$37,500	Patient Care
Univ of North Carolina at Chapel Hill
566001393	$652,667	Research
Univ of Texas MD Anderson Cancer Center
746001118	$731,645	Research, Patient Care
University of California at San Francis
946036493	$283,458	Research
University of California-Davis
946036494	$100,000	Research
University of Chicago
362177139	$200,000	Research
University of Kansas Center for Research
480680117	$59,518	Research
University of Kentucky Research Fndn
616033693	$224,933	Research
University of Michigan
386006309	$180,000	Research
University of North Carolina
566001393	$220,000	Research
University of Pennsylvania
231352685	$571,450	Research, Patient Care
University of Pittsburgh
250966691	$29,958	Research
University of Pittsburgh
250965591	$135,319	Research
University of Texas at Health Science Ctr
741587488	$53,764	Research
University of Utah
876000525	$292,180	Research
UT HSC - San Antonio
741586031	$393,124	Research
UT Southwestern Medical Center
746000203	$150,000	Research
Vanderbilt University Medical Center
620476822	$486,465	Research
Virginia Commonwealth University
546001758	$240,000	Research
Wake Forest University Health Sciences
223849199	$59,926	Research
Washington University at St Louis
430653611	$131,984	Research
Wayne State University
366028429	$33,240	Research
Weill Medical College of Cornell Univ
131623978	$100,000	Research
Yale University
030179440	$307,788	Research

Field	Value	IRS element (for citing)
Total501c3 Org	61	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (2 entries)

Grant TypeGrantTypeTxt	RecipientRecipientCnt	Cash GrantCashGrantAmt
Patient Care Assistance @ $500	11994	$3,081,750
Patient Care Assistance @ $750	4109	$5,997,000

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds.	FormAndLineReferenceDesc
Explanation	SUSAN G. KOMEN'S (KOMEN) POLICIES FOR MANAGING GRANTS FROM THE TIME OF PRE-AWARD THROUGH CLOSEOUT ARE DESIGNED TO MAXIMIZE FLEXIBILITY WHILE MAINTAINING A HIGH STANDARD OF ACCOUNTABILITY AND PRESERVING THE INTEGRITY OF THE REVIEW AND AWARD PROCESS. KOMEN REQUIRES ALL GRANTEES TO SIGN A GRANT AGREEMENT SETTING FORTH THE TERMS OF THE GRANT, INCLUDING: PURPOSE, AMOUNT, BUDGETARY RESTRICTIONS, DURATION, PAYMENT SCHEDULE, REPORTING REQUIREMENTS, AUDIT, AND EARLY TERMINATION RIGHTS. FOR RESEARCH GRANTS, SCIENTIFIC PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED THROUGHOUT THE GRANT TERM BY A PH.D. OR MASTERS-LEVEL RESEARCH GRANT MANAGER. FOR COMMUNITY HEALTH AND EDUCATION GRANTS, PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED OR SUPERVISED THROUGHOUT THE GRANT TERM BY QUALIFIED PROFESSIONALS SERVING AS GRANTS MANAGERS. AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, GRANTEES ARE REQUIRED TO SUBMIT PROGRESS AND FINANCIAL REPORTS DETAILING PROGRESS TOWARD AIMS AND OBJECTIVES, MAJOR ACCOMPLISHMENTS, KEY DELIVERABLES AND CHALLENGES ENCOUNTERED, WITH A FULL ACCOUNTING OF GRANT FUNDS EXPENDED (ACTUAL VERSUS BUDGETED EXPENSES) AND WRITTEN JUSTIFICATION OF EXPENSES. AS APPROPRIATE, THE GRANTS MANAGER MAY CONDUCT SITE VISITS WITH GRANTEES TO GAIN A BETTER UNDERSTANDING OF THEIR WORK AND ADDRESS ANY CHALLENGES IMPACTING THE FUNDED PROGRAM. ALL GRANT FUNDS MUST BE EXPENDED IN ACCORDANCE WITH THE PROJECT'S APPROVED BUDGET AND ARE DISBURSED IN ACCORDANCE WITH THE SCHEDULE DOCUMENTED WITHIN THE GRANT AGREEMENT. REQUESTS FOR CHANGES TO THE DESIGN OF THE FUNDED PROJECT OR BUDGET ARE SUBJECT TO PRIOR APPROVAL BY KOMEN IN ACCORDANCE WITH THE TERMS OF THE GRANT AGREEMENT. AS PART OF ITS OVERSIGHT PRACTICES, THE TERMS OF THE GRANT AGREEMENT MAY PROVIDE KOMEN WITH, AMONG OTHER THINGS, THE RIGHT TO REQUEST WITH REASONABLE PRIOR NOTICE TO THE GRANTEE: (1) ADDITIONAL PROGRESS AND/OR FINANCIAL REPORTING FROM THE GRANTEE, (2) GRANTEE PARTICIPATION IN SITE VISITS, TELEPHONE CONFERENCES, PRESENTATIONS, OR OTHER SPEAKING ENGAGEMENTS, AND (3) WITH PRIOR WRITTEN NOTICE, ADJUSTMENT TO THE PROJECT REPORTING PERIOD AND ASSOCIATED DISBURSEMENT OF GRANT FUNDS AT ANY TIME DURING THE GRANT TERM. SEE SCHEDULE O, PART IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Form990 Of Other Organizations	Yes (X)	Form990OfOtherOrganizationsInd
Written Employment Contract	Yes (X)	WrittenEmploymentContractInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	false	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	false	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	false	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	false	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	false	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	false	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	false	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	false	AnyNonFixedPaymentsInd
Initial Contract Exception	false	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (12 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
Dana Brown
Chief Operating Officer (Term 3/31/22)	$136,744	$0	$46,800	$0	$1,213	$0	$4,200	$0	$1,380	$0	$190,337	$0	$0	$0
Eunice Nakamura
General Counsel and Corporate Secretary	$244,099	$0	$28,200	$0	$1,579	$0	$16,754	$0	$6,933	$0	$297,565	$0	$0	$0
Paula Schneider
President and CEO	$631,275	$0	$252,285	$0	$4,604	$0	$20,057	$0	$7,558	$0	$915,779	$0	$0	$0
Ria Williams
Chief Fin & Ops Officer	$282,221	$0	$34,800	$0	$2,055	$0	$16,874	$0	$13,761	$0	$349,711	$0	$0	$0
Lori Maris
SVP, OPS SERVICES & SUPPORT	$212,699	$0	$25,800	$0	$1,734	$0	$8,401	$0	$6,948	$0	$255,582	$0	$0	$0
Catherine Olivieri
SVP, Human Resources	$243,713	$0	$30,000	$0	$3,362	$0	$14,714	$0	$11,705	$0	$303,494	$0	$0	$0
Victoria Smart
SVP, Mission	$294,149	$0	$34,800	$0	$2,528	$0	$13,911	$0	$1,794	$0	$347,182	$0	$0	$0
Srinivasu Avadhanula
VP, BI Platform & Engineering	$223,372	$0	$24,960	$0	$1,460	$0	$12,379	$0	$11,235	$0	$273,406	$0	$0	$0
Kari Bodell
VP, Development Programs Strategy	$213,599	$0	$24,600	$0	$1,426	$0	$12,375	$0	$1,794	$0	$253,794	$0	$0	$0
Sarah Rosales
VP, Corporate Partnerships	$227,827	$0	$28,200	$0	$1,331	$0	$13,683	$0	$15,668	$0	$286,709	$0	$0	$0
Catherine Stone
VP, Community Health	$189,677	$0	$22,000	$0	$1,383	$0	$11,337	$0	$1,794	$0	$226,191	$0	$0	$0
Michelle Strong
VP, Marketing Strategy	$207,548	$0	$24,000	$0	$1,632	$0	$14,372	$0	$7,988	$0	$255,540	$0	$0	$0

Schedule M IRS990ScheduleM

Food Inventory FoodInventoryGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	56	ContributionCnt
Noncash Contributions Rpt F990	$148,547	NoncashContributionsRptF990Amt
Method Of Determining Revenues	Cost	MethodOfDeterminingRevenuesTxt

Other Non Cash Contri Table OtherNonCashContriTableGrp (2 entries)

Non Cash CheckboxNonCashCheckboxInd	DescDesc	ContributionContributionCnt	Noncash Contributions Rpt F990NoncashContributionsRptF990Amt	Method Of Determining RevenuesMethodOfDeterminingRevenuesTxt
Yes (X)	Gift bags/Gift Cards	53	$424,435	Cost
Yes (X)	Event Supplies	7	$19,495	Cost

Field	Value	IRS element (for citing)
Form8283 Received	2	Form8283ReceivedCnt
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	false	ReviewProcessUnusualNCGiftsInd
Third Parties Used	false	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule M, Part I Explanations of reporting method for number of contributions	FormAndLineReferenceDesc
Explanation	Food inventory - Food & Beverage Number of contributions Other - Gift bags/Gift Cards Number of contributions	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (14 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Form 990, Part I, Line 6 VOLUNTEERS	VOLUNTEERS SERVE IN A VARIETY OF WAYS, BUT THE GREATEST NUMBERS OF VOLUNTEERS ASSIST WITH THE MORE THAN PINK WALKS, RACE FOR THE CURE RUNS, THE SUSAN G. KOMEN 3 DAY SERIES, AND ADVOCACY PROGRAMS.
Form 990, Part III, Line 4 Program service accomplishments	SUSAN G. KOMEN'S MISSION IS TO SAVE LIVES FROM BREAST CANCER BY FINDING BREAKTHROUGHS TO PREVENT, DETECT, TREAT, AND CURE BREAST CANCER, AND BY MEETING THE MOST CRITICAL NEEDS IN COMMUNITIES TO ENSURE EVERYONE GETS THE BREAST CANCER CARE THEY NEED WHEN THEY NEED IT. KOMEN TAKES A 360 DEGREE APPROACH TO FIGHT BREAST CANCER THROUGH: - RESEARCH, TO DRIVE BREAKTHROUGHS THAT WILL BRING US NEW KNOWLEDGE AND ADVANCES IN CARE FOR ALL. -COMMUNITY HEALTH, TO EMPOWER PEOPLE WITH TRUSTWORTHY INFORMATION AND SUPPORT PEOPLE IN THEIR BREAST HEALTH JOURNEY THROUGH DIRECT SERVICES, COMMUNITY PROGRAMS AND HEALTH SYSTEMS CHANGE. - AND PUBLIC POLICY, WHERE WE ADVOCATE FOR POLICIES TO CREATE SYSTEMIC AND LASTING CHANGES THAT WILL FUND AND FACILITATE RESEARCH AND ALLEVIATE THE BURDEN ON PATIENTS AND PROTECT ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL. KOMEN IS A LEADING GLOBAL BREAST CANCER ORGANIZATION, HAVING FUNDED MORE BREAST CANCER RESEARCH THAN ANY OTHER NONPROFIT OUTSIDE OF THE U.S. GOVERNMENT WHILE PROVIDING REAL-TIME HELP TO THOSE FACING THE DISEASE. SINCE ITS FOUNDING IN 1982, KOMEN HAS INVESTED OVER $1.1 BILLION IN BREAST CANCER RESEARCH IN MORE THAN 2800 GRANTS AND MORE THAN 500 CLINICAL TRIALS CONDUCTED BY THOUSANDS OF THE WORLD'S BEST AND BRIGHTEST RESEARCHERS ACROSS THE US AND AROUND THE WORLD. KOMEN HAS ALSO PROVIDED OVER $3.2 BILLION IN COMMUNITY INVESTMENT FOR PATIENT NAVIGATION, SCREENING, DIAGNOSIS, TREATMENT, EDUCATION, ADVOCACY, AND PSYCHOSOCIAL SUPPORT PROGRAMS SERVING MILLIONS OF PEOPLE IN MORE THAN 60 COUNTRIES WORLDWIDE. KOMEN WAS FOUNDED BY NANCY G. BRINKER, WHO PROMISED HER SISTER, SUSAN G. KOMEN, THAT SHE WOULD END THE DISEASE THAT CLAIMED SUZY'S LIFE. WITH THIS INVESTMENT, KOMEN IS SUPPORTING LABORATORY RESEARCH, TRANSLATIONAL STUDIES, AND CLINICAL TRIALS THAT ARE PAVING THE ROAD WITH SCIENTIFIC DISCOVERIES THAT ARE: - UNRAVELLING THE BIOLOGY OF BREAST CANCER, - LEADING TO THE DEVELOPMENT OF NEW BREAST CANCER DRUGS, - DEVELOPMENT OF NEW TECHNOLOGIES AND TESTS, AND - NEW INTERVENTIONS THAT ARE CHANGING THE STANDARD OF BREAST CANCER CARE AND IMPROVING THE DELIVERY OF THAT CARE. OUR GOAL IS TO ADVANCE PERSONALIZED MEDICINE AND IMPROVE HEALTH OUTCOMES FOR EVERYONE. KOMEN HAS HAD MORE THAN 3,100 RESEARCH DISCOVERIES THAT ARE MOVING US CLOSER TO THAT GOAL. THIS INCLUDES OVER 700 NEW DISCOVERIES FOCUSED ON METASTATIC BREAST CANCER, MORE THAN 1,200 POTENTIAL TREATMENTS AND NEARLY 400 NEW STRATEGIES TO ELIMINATE BREAST CANCER DISPARITIES. THEY INCLUDE SUCH THINGS AS NEW BIOMARKERS, NEW DRUG TARGETS, NEW TREATMENTS, AND NEW HEALTH CARE DELIVERY TOOLS IN PAVING THIS ROAD WITH SCIENTIFIC DISCOVERIES, WE'RE ALSO PAVING IT WITH HOPE. THE HOPE THAT NEW WAYS TO DETECT, DIAGNOSE, TREAT, PREVENT AND, ULTIMATELY, CURE BREAST CANCER ARE AROUND THE CORNER AND THERE WHEN PEOPLE WITH BREAST CANCER NEED THEM TO ALLOW THEM TO LIVE LONGER, WITH IMPROVED QUALITY OF LIFE. RESEARCH SINCE ITS FOUNDING IN 1982, KOMEN'S RESEARCH INVESTMENTS HAVE CONTRIBUTED TO MANY MAJOR ADVANCES IN BREAST CANCER SCIENCE. THE PROGRESS HAS BEEN SIGNIFICANT - TODAY, WE KNOW THAT BREAST CANCER IS MORE THAN A SINGLE DISEASE. WE HAVE A BETTER UNDERSTANDING OF THE GENETICS OF BREAST CANCER AND THE CRITICAL NEED TO TAILOR SCREENING, DIAGNOSIS, TREATMENT, AND PREVENTION STRATEGIES TO INDIVIDUALS THROUGH ADVANCES IN PRECISION MEDICINE. KOMEN'S RESEARCH PROGRAMS ARE FOCUSED ON BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER THROUGH BETTER APPROACHES FOR EARLY DETECTION AND DIAGNOSIS, UNDERSTANDING METASTASIS AND RECURRENCE, DEVELOPING NOVEL THERAPIES FOR ALL STAGES OF BREAST CANCER, AND DEVELOPING NEW APPROACHES TO ADDRESS DISPARITIES IN BREAST CANCER OUTCOMES, WITH THE GOAL OF SUPPORTING WORK THAT HAS SIGNIFICANT POTENTIAL TO LEAD TO NEW TREATMENTS, TECHNOLOGIES AND INTERVENTIONS. KOMEN'S RESEARCH PROGRAMS ARE GUIDED BY 54 OF THE WORLD'S LEADERS IN BREAST CANCER RESEARCH, ONCOLOGY AND ADVOCACY. THE SCIENTIFIC ADVISORY BOARD ASSISTS KOMEN IN SETTING ITS RESEARCH STRATEGY AND PRIORITIZING ITS RESEARCH INVESTMENT. THE KOMEN SCHOLARS LEAD AND PARTICIPATE IN KOMEN'S WORLD-CLASS SCIENTIFIC PEER REVIEW PROCESS. OUR ADVOCATES IN SCIENCE BRING THE COLLECTIVE PATIENT VOICE TO KOMEN'S RESEARCH PROGRAMS AND SCIENTIFIC ACTIVITIES, EMPHASIZING URGENCY AND PATIENT IMPACT. THIS YEAR WE ANNOUNCED THE NEW CLASS OF NINE ESTEEMED BREAST CANCER RESEARCHERS AND TWO NEW PATIENT ADVOCATES TO THE KOMEN SCHOLARS. THESE INDIVIDUALS JOIN AN EXCLUSIVE GROUP OF BREAST CANCER RESEARCHERS, CLINICIANS AND ADVOCATES WHO HELP GUIDE THE ORGANIZATION'S WORK TO SAVE LIVES AND END BREAST CANCER. KOMEN AWARDS GRANTS TO INDIVIDUAL SCIENTISTS, RESEARCH TEAMS, AND ORGANIZATIONS AROUND THE WORLD THROUGH A FAIR, TRANSPARENT, RIGOROUS, AND COMPETITIVE REVIEW PROCESS THAT ENSURES MAXIMUM IMPACT FOR OUR RESEARCH INVESTMENT. IN FY23, KOMEN AWARDED 49 GRANTS THROUGH ITS RESEARCH PROGRAMS TO SUPPORT SCIENTIFIC RESEARCH, IN THE UNITED STATES, PUERTO RICO AND PORTUGAL. CAREER CATALYST RESEARCH GRANTS SUPPORT EARLY CAREER INVESTIGATORS CONDUCTING OUTSTANDING RESEARCH FOCUSED THE DEVELOPMENT OF NEXT GENERATION-TARGETED THERAPIES AND THE DEVELOPMENT OF INTERVENTIONS TO ELIMINATE BREAST CANCER HEALTH DISPARITIES. LEADERSHIP GRANTS SUPPORT KOMEN SCHOLARS PURSUING INNOVATIVE RESEARCH PROJECTS WHICH WILL IMPROVE THE UNDERSTANDING, DETECTION, TREATMENT OR PREVENTION OF BREAST CANCER, WITH A FOCUS ON CONQUERING METASTATIC BREAST CANCER AND ELIMINATING BREAST CANCER DISPARITIES. A SUPPLEMENT TO PROMOTE INCLUSION FOR RESEARCH EXCELLENCE (ASPIRE) GRANTS ARE SUPPLEMENT GRANTS TO AMPLIFY EXISTING FUNDING TO ENHANCE THE DIVERSITY OF THE BREAST CANCER RESEARCH WORKFORCE BY PROVIDING ESTABLISHED BREAST CANCER SCIENTISTS WITH SUPPLEMENTAL FUNDING TO SUPPORT RESEARCH TRAINEES FROM COMMUNITIES HISTORICALLY MINORITIZED AND MARGINALIZED IN RESEARCH. THE 49 RESEARCH GRANTS AWARDED IN FY23 ARE: CAREER CATALYST RESEARCH GRANTS: JULIA MCGUINNESS, M.D., FROM COLUMBIA UNIVERSITY, WILL DEVELOP A NEW MODEL TO ACCURATELY PREDICT BREAST CANCER RISK FROM SCREENING MAMMOGRAMS. SHE WILL UTILIZE SAMPLES FROM A RACIALLY/ETHNICALLY DIVERSE POPULATION IN NEW YORK CITY TO ENSURE THE MODEL REPRESENTS ALL BREAST CANCER PATIENTS. SHEARWOOD MCCLELLAND, M.D., FROM CASE WESTERN UNIVERSITY IS TESTING HOW PATIENT NAVIGATION IMPACTS ACCESS TO SHORT-COURSE RADIATION THERAPY (RT) FOR BLACK BREAST CANCER PATIENTS AND HOW FINANCIAL TOXICITIES INFLUENCE RT ADHERENCE. THE GOAL OF THIS RESEARCH IS TO DEMONSTRATE HOW PATIENT NAVIGATION AND SHORT-COURSE RT CAN ALLEVIATE FINANCIAL BURDEN AND HELP BLACK BREAST CANCER PATIENTS COMPLETE THEIR RT TREATMENTS. THIS WORK WILL ALSO CREATE A NEW EDUCATIONAL TOOL FOR PATIENT NAVIGATORS THAT EDUCATES ON THE USE OF SHORT-COURSE RT TO OVERCOME EXISTING BARRIERS TO CARE AND IMPROVE TREATMENT OUTCOMES. ANAND NARAYAN, M.D., PH.D., FROM THE UNIVERSITY OF WISCONSIN-MADISON, WILL CREATE A FREE ELECTRONIC HEALTH RECORDS PROGRAM THAT WILL IMPROVE HOW CLINICIANS MONITOR DELAYS IN MAMMOGRAMS, AND WILL ALSO QUANTIFY BARRIERS TO SCREENING AND CREATE PATIENT-CENTERED INTERVENTIONS THAT IMPROVE ACCESS TO BREAST IMAGING. THE GOAL IS TO IMPROVE TIMELY ACCESS TO MAMMOGRAMS TO CATCH MORE CANCERS EARLIER, PARTICULARLY IN MINORITY, RURAL AND UNINSURED POPULATIONS. BRUNO BARUFALDI, PH.D., FROM THE UNIVERSITY OF PENNSYLVANIA, WILL DEVELOP AN ARTIFICIAL INTELLIGENCE SYSTEM THAT INCORPORATES RACIALLY UNBIASED DESCRIPTORS OF BREAST COMPLEXITY AND SOCIOECONOMIC STATUS TO BETTER IDENTIFY INDIVIDUALS THAT NEED SUPPLEMENTAL BREAST SCREENING. THE GOAL OF THIS STUDY IS TO ENSURE ALL PATIENTS RECEIVE ACCESS TO THE SCREENING TESTS THEY NEED TO IDENTIFY BREAST CANCER EARLY. PRIYANKA VERMA, PH.D., FROM WASHINGTON UNIVERSITY IN ST. LOUIS, WILL AIM TO DEVELOP A NEW THERAPY FOR BRCA-MUTANT BREAST CANCERS THAT WILL TARGET AMPLIFIED IN LIVER CANCER 1 (ALC1), A PROTEIN THAT, WHEN INHIBITED, CAUSES DEATH OF BRCA-MUTANT BREAST CANCER CELLS WITH MINIMAL DAMAGE TO SURROUNDING HEALTHY CELLS. THE GOAL OF THIS STUDY IS TO PROVIDE AN INNOVATIVE AND PROMISING NEW THERAPY FOR HIGH-RISK WOMEN WITH BRCA MUTATIONS WHO CURRENTLY HAVE LIMITED TREATMENT OPTIONS. AIMILIA GASTOUNIOTI, PH.D., FROM WASHINGTON UNIVERSITY IN ST. LOUIS, WILL USE DIGITAL MAMMOGRAMS AND BREAST TOMOSYNTHESIS FROM BLACK WOMEN TO ENHANCE ARTIFICIAL INTELLIGENCE (AI) MODELS THAT BETTER PREDICT BREAST CANCER RISK FOR THIS GROUP, WHO HAVE BEEN HISTORICALLY OVERLOOKED IN PAST RISK ASSESSMENTS. THE GOAL OF THIS WORK IS TO DEVELOP CLINICALLY RELEVANT AI METHODS THAT DIFFERENTIATE BETWEEN HIGH- AND LOW-RISK INDIVIDUALS, AND ADVANCE BREAST CANCER RISK ASSESSMENTS AND PRECISION SCREENING RECOMMENDATIONS FOR BLACK WOMEN.
Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	SARAH HILL, M.D., PH.D., FROM DANA- FARBER CANCER INSTITUTE, WILL INVESTIGATE THE ROLE OF A DNA DAMAGE REPAIR PROTEIN CALLED HBO1 IN TRIPLE NEGATIVE BREAST CANCER (TNBC). DR. HILL'S RESEARCH WILL DETERMINE IF HBO1 IS A PROMISING PHARMACEUTICAL TARGET FOR PATIENTS WITH TNBC, FOR WHOM TARGETED THERAPIES ARE URGENTLY NEEDED. LUCIA BORRIELLO, PH.D., FROM TEMPLE UNIVERSITY, WILL USE PRECLINICAL MODELS AND PATIENT DATA TO INVESTIGATE WHAT CAUSES BREAST TUMOR CELLS TO SPREAD AND LIE DORMANT BEFORE DEVELOPING INTO A DETECTABLE METASTATIC TUMOR. BY UNDERSTANDING THE CAUSES OF DORMANCY, DR. BORRIELLO HOPES THAT THERAPEUTIC STRATEGIES CAN BE DEVELOPED TO PREVENT DORMANT CELLS FROM DEVELOPING INTO METASTATIC BREAST CANCER. SHEHERYAR KABRAJI, BMBCH, OF ROSWELL PARK, WILL IDENTIFY MOLECULAR FEATURES ON TUMOR CELLS THAT CAUSE BLACK WOMEN WITH TRIPLE NEGATIVE BREAST CANCER (TNBC) TO RESPOND DIFFERENTLY TO NEOADJUVANT CHEMOTHERAPY THAN OTHER POPULATIONS, AND DETERMINE WHETHER THESE FEATURES COULD SERVE AS BIOMARKERS FOR THE DEVELOPMENT OF PERSONALIZED TNBC TREATMENTS. THIS RESEARCH COULD HELP REDUCE EXISTING DISPARITIES IN CHEMOTHERAPY BENEFITS AND ENSURE ALL TNBC PATIENTS HAVE EQUITABLE ACCESS TO THE BEST TREATMENTS POSSIBLE.NATHAN MERRILL, PH.D., FROM THE UNIVERSITY OF MICHIGAN, WILL EVALUATE A NOVEL DRUG COMBINATION THAT INCLUDES DNA DAMAGE RESPONSE (DDR) THERAPIES AND TREATMENTS THAT PREVENT TUMOR CELL GROWTH. USING PRECLINICAL MODELS AND CLINICAL MARKERS, THE GOAL OF THIS STUDY IS TO TARGET MARKERS OF SENSITIVITY AND RESISTANCE IN TRIPLE NEGATIVE BREAST CANCER (TNBC) TO HELP IDENTIFY DRUG COMBINATIONS THAT OFFER A PROMISING THERAPEUTIC STRATEGY FOR TNBC PATIENTS. GANG XIN, PH.D., FROM THE OHIO STATE UNIVERSITY, WILL INVESTIGATE HOW A POTENTIAL PROTEIN SWITCH COULD REGULATE TUMOR-ASSOCIATED MACROPHAGES (TAMS), A TYPE OF IMMUNE CELL, AND THE IMPACT ON THE RESPONSE OF BREAST TUMORS TO IMMUNOTHERAPY. THE GOAL OF THIS STUDY IS TO DEVELOP A TARGETED THERAPY THAT IMPROVES THE EFFICACY OF IMMUNOTHERAPY. ADRIENNE WAKS, M.D., FROM DANA FARBER CANCER INSTITUTE, WILL EXPLORE THE RELATIONSHIP BETWEEN ANTI-HER2 ANTIBODY THERAPY, ANTI-TUMOR IMMUNE RESPONSES AND CLINICAL OUTCOMES FOR PEOPLE WITH HER2+ BREAST CANCER. THE HOPE IS THAT THIS STUDY WILL IDENTIFY WHICH HER2+ PATIENTS WILL BENEFIT MOST FROM ANTI-HER2 THERAPIES AND GUIDE DEVELOPMENT OF NEW THERAPIES THAT WILL OVERCOME IMMUNE RESISTANCE FOR THESE PATIENTS. ERIKA CROSBY, PH.D., FROM DUKE UNIVERSITY, WILL USE A MOUSE MODEL TO INVESTIGATE HOW OBESITY IMPACTS RESPONSE TO IMMUNOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER (TNBC), AND EVALUATE WHETHER THESE STUDY RESULTS CORRELATE WITH OBSERVATIONS FOR WOMEN PARTICIPATING IN THE CAROLINA BREAST CANCER STUDY. THIS RESEARCH WILL PROVIDE INSIGHT INTO THE PARADOX OF IMMUNOTHERAPY, OBESITY AND THEIR POTENTIAL EFFECTS IN TNBC. ISAAC CHAN, M.D., PH.D., FROM THE UNIVERSITY OF TEXAS SOUTHWESTERN, WILL CONDUCT A STUDY USING LYMPHOCYTES CALLED NATURAL KILLER CELLS THAT SUPPORT BREAST CANCER METASTASIS AND REPROGRAM THEM TO RETURN TO THEIR ORIGINAL TUMOR-FIGHTING ACTIVITY. THIS STUDY WILL HELP IDENTIFY PATIENTS WHO WOULD MOST BENEFIT FROM IMMUNOTHERAPIES, AS WELL AS INFLUENCE STRATEGIES FOR THE FUTURE DEVELOPMENT OF DRUGS THAT WILL MANIPULATE IMMUNE CELLS TO FIGHT METASTATIC TUMORS. ASPIRE GRANTS JULIE PALMER, SC.D., M.P.H., FROM BOSTON UNIVERSITY, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER ETIENNE X. HOLDER, PH.D., WHO WILL EXAMINE NEIGHBORHOOD-LEVEL PSYCHOSOCIAL FACTORS TO DETERMINE WHETHER CHRONIC PSYCHOSOCIAL DISTRESS LEADS TO THE ADVERSE BIOLOGICAL OUTCOMES THAT CONTRIBUTE TO THE DISPROPORTIONATELY HIGH BREAST CANCER MORTALITY EXPERIENCED BY BLACK WOMEN. THE GOAL OF THIS RESEARCH IS TO EXPLAIN THIS HIGH MORTALITY RATE AND DEVELOP INDIVIDUAL-LEVEL INTERVENTIONS SUCH AS MEDICATIONS AND MINDFULNESS TRAINING, AS WELL AS THE DEVELOPMENT OF NEW PROGRAMS AND POLICIES, TO COUNTERACT THE EFFECTS OF CHRONIC PSYCHOSOCIAL DISTRESS EXPERIENCED IN THESE COMMUNITIES. JENNIFER GUERRIERO, PH.D., FROM BRIGHAM AND WOMEN'S HOSPITAL, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER CARLOS WAGNER DE SOUZA WANDERLEY, PH.D., WHO IS STUDYING HOW DIFFERENT FACTORS IN THE TUMOR MICROENVIRONMENT IMPACT THE RESPONSE OF BRCA-MUTANT TUMOR CELLS TO PARP INHIBITORS, A TYPE OF TARGETED THERAPY FOR TREATING TUMORS WITH A BRCA MUTATION. THE GOAL OF THIS RESEARCH IS TO PROVIDE INSIGHT INTO POTENTIAL COMBINATION THERAPIES THAT WOULD IMPROVE THE RESPONSE TO PARP INHIBITORS. HARIKRISHNA NAKSHATRI, PH.D., FROM INDIANA UNIVERSITY, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE ADEDEJI. K. ADEBAYO, D.V.M., WHO WILL STUDY THE IMPACT OF OXYGEN EXPOSURE ON TUMOR CELLS DERIVED FROM TUMORS ACQUIRED FROM THE KOMEN TISSUE BANK AT THE INDIANA UNIVERSITY SIMON COMPREHENSIVE CANCER CENTER. THE GOAL OF THIS RESEARCH IS TO IDENTIFY HOW DIFFERENT OXYGEN CONDITIONS MODIFY TUMOR SIGNALING, GROWTH AND RESPONSE TO BREAST CANCER TREATMENTS. MARIA SOSA, PH.D., FROM ALBERT EINSTEIN COLLEGE OF MEDICINE, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER CAROLINA RODRIGUEZ TIRADO, PH.D., WHO WILL INVESTIGATE HOW THE PROTEIN ZFP296 ALLOWS DISSEMINATED, DORMANT CANCER CELLS TO FORM A METASTATIC TUMOR. THE GOALS OF THIS PROJECT ARE TO ILLUSTRATE THE ROLE OF ZFP296 IN REACTIVATING DORMANT CANCER CELLS, IDENTIFY POSSIBLE THERAPIES AGAINST ZFP296, AND ULTIMATELY, TO USE THESE FINDINGS TO HELP PREVENT BREAST CANCER METASTASIS. JUSTIN BALKO, PH.D., PHARM.D., FROM VANDERBILT UNIVERSITY, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE STUDENT BRANDIE TAYLOR, WHO WILL INVESTIGATE WHY HETEROGENEOUS LEVELS OF THE PROTEIN MHC-I WITHIN A SINGLE TUMOR CAN NEGATIVELY IMPACT BREAST TUMOR RESPONSE TO IMMUNOTHERAPY. THESE STUDIES WILL LEAD TO AN INCREASED UNDERSTANDING OF WHY SOME TUMORS DON'T RESPOND TO IMMUNOTHERAPY. TASNEEM BAWA-KHALFE, PH.D., FROM THE UNIVERSITY OF HOUSTON, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO KACIE WAITERS, WHO WILL INVESTIGATE HOW THE MODIFICATION OF DNA VIA A PROCESS CALLED SUMOYLATION (SUMO) REDUCES TREATMENT EFFICACY AND DRIVES PROGRESSION OF BREAST TUMORS IN ADVANCED ENDOCRINE RESISTANT HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER. THE GOAL OF THIS STUDY IS TO DEMONSTRATE HOW SUMO IS INVOLVED IN THIS PROCESS AND TO EVALUATE AND PRODUCE NOVEL THERAPIES THAT WILL PREVENT TUMOR PROGRESSION. MICHELLE MARTINEZ-MONTEMAYOR, PH.D., FROM THE UNIVERSIDAD CENTRAL DEL CARIBE, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER LUZ V. ARROYO-CRUZ, PH.D., WHOSE STUDY WILL INVESTIGATE WHETHER A NATURAL STEROIDAL COMPOUND CAN TARGET SPECIFIC PROTEINS IN TUMOR CELLS, IMPAIRING THEM AND CAUSING THEM TO DIE, WITHOUT DAMAGING SURROUNDING HEALTHY CELLS. THE GOAL OF THIS STUDY IS TO DEMONSTRATE HOW THIS NATURAL COMPOUND CAN LEAD TO TUMOR CELL DEATH. MATTHEW BRADY, M.D., FROM THE UNIVERSITY OF CHICAGO, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT DOCTORAL STUDENT BRIANA BANKS FOR THIS RESEARCH, WHICH WILL DETERMINE WHETHER HIGHER LEVELS OF A STEROID HORMONE CALLED GLUCOCORTICOID (GC) MAY INCREASE THE RISK OF BREAST CANCER DURING CRITICAL TIMES OF DEVELOPMENT LIKE PUBERTY. USING PRECLINICAL MODELS OF BREAST CANCER, THEY WILL IDENTIFY HOW GC RELEASE AFFECTS THE DEVELOPMENT OF MAMMARY GLAND DUCTS AND DETERMINE WHETHER USE OF A GC-BLOCKING DRUG CAN REVERSE MANY OF THESE CHANGES THAT INCREASE BREAST CANCER RISK. CHRISTY HAGAN, PH.D., OF THE UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT DOCTORAL STUDENT HARMONY SAUNDERS, WHO WILL INVESTIGATE HOW PROGESTERONE TREATMENTS IMPACT BREAST CANCER. THIS STUDY WILL DETERMINE WHETHER ACTIVATION OF PROGESTERONE RECEPTORS IN THE MAMMARY GLAND ALLOWS TUMORS TO ESCAPE DETECTION BY THE IMMUNE SYSTEM AND AVOID CELL DEATH.
Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	JULIE RHOADES, PH.D., OF VANDERBILT UNIVERSITY MEDICAL CENTER, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT DOCTORAL STUDENT LOGAN NORTHCUTT, WHO WILL INVESTIGATE HOW ESTROGEN RECEPTOR (ER) SIGNALING IS REGULATED WHEN TUMOR CELLS METASTASIZE TO THE BONE USING A NOVEL MODEL OF BONE STIFFNESS. THE INFORMATION GAINED FROM THIS STUDY WILL HELP RESEARCHERS UNDERSTAND HOW BREAST CANCER CELLS RESPOND TO ENDOCRINE THERAPY IN THE BONE, THE MOST COMMON SITE OF METASTASIS IN ER+ BREAST CANCER. ZACHARY T. SCHUG, PH.D., OF THE UNIVERSITY OF PENNSYLVANIA, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT DOCTORAL STUDENT KELSEY SALCIDO, WHO WILL INVESTIGATE THE RELATIONSHIP BETWEEN ALCOHOL CONSUMPTION AND BREAST CANCER RISK. BY DETERMINING WHETHER THE ACETATE FOUND IN ALCOHOLIC BEVERAGES SERVES AS A FUEL FOR TUMOR METABOLISM AND GROWTH. THE GOAL OF THIS STUDY IS TO IDENTIFY WAYS TO MITIGATE THE IMPACT OF ALCOHOL CONSUMPTION ON BREAST CANCER RISK. LEADERSHIP GRANTS: SCIENTIFIC ADVISORY BOARD MEMBER ALAN ASHWORTH, PH.D., OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, WILL IDENTIFY GENES THAT ALTER RESPONSE TO NEW FORMS OF IMMUNOTHERAPY CALLED CAR-T AND NK CELL THERAPY. THE GOAL OF THIS RESEARCH IS TO BRING NEW OPTIONS FOR IMMUNOTHERAPY TO PATIENTS WITH METASTATIC BREAST CANCER. KOMEN SCHOLAR DONALD MCDONNELL, PH.D., OF DUKE UNIVERSITY, RECEIVED FUNDS TO STUDY A PROTEIN CALLED LYPD3, WHICH IS ASSOCIATED WITH AGGRESSIVE BREAST CANCER. THROUGH THIS RESEARCH, DR. MCDONNELL HOPES TO DISCOVER NEW DRUGS FOR METASTATIC BREAST CANCER. KOMEN SCHOLAR, BEN H. PARK, M.D., PH.D., OF VANDERBILT UNIVERSITY MEDICAL CENTER, WILL INVESTIGATE WHY MUTATIONS IN THE SF3B1 PROTEIN CAUSE BREAST CANCER. BY UNDERSTANDING HOW THESE MUTATIONS CAUSE BREAST CANCER, DR. PARK HOPES TO IDENTIFY NEW STRATEGIES TO THERAPEUTICALLY TARGET BREAST TUMORS WITH SF3B1 MUTATIONS. SCIENTIFIC ADVISORY BOARD MEMBER LISA A. CAREY, M.D., SC.M., OF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, WILL INVESTIGATE HOW TUMORS DEVELOP RESISTANCE TO ANTIBODY- DRUG CONJUGATE (ADC) TREATMENTS. THE GOAL OF THIS RESEARCH IS TO IDENTIFY BIOMARKERS THAT INFORM ONCOLOGISTS HOW WELL A BREAST CANCER PATIENT'S TUMOR RESPONDS TO TREATMENT WITH ADCS KOMEN SCHOLAR DAWN HERSHMAN, M.D., OF COLUMBIA UNIVERSITY, WILL CONDUCT A CLINICAL TRIAL TO DETERMINE IF INTERVENTIONS TO RELIEVE FOOD INSECURITY IMPROVES THE QUALITY OF LIFE FOR PATIENTS WITH METASTATIC BREAST CANCER THAT STRUGGLE WITH FOOD INSECURITY. THE GOAL OF THIS STUDY IS TO INVESTIGATE THE FEASIBILITY OF THESE INTERVENTIONS, WHILE PAVING THE WAY FOR A LARGER CLINICAL TRIAL THAT WILL INVESTIGATE HOW INTERVENTIONS TO RELIEVE FOOD INSECURITY IMPACT BREAST CANCER OUTCOMES. SCIENTIFIC ADVISORY BOARD MEMBER LISA NEWMAN, M.D., OF WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY, WILL STUDY THE GENETIC MAKEUP OF BREAST TUMORS FROM WOMEN OF AFRICAN ANCESTRY. THE GOAL OF THIS RESEARCH IS TO BETTER UNDERSTAND THE UNIQUE FEATURES OF THESE BREAST TUMORS TO ELIMINATE RACIAL DISPARITIES IN BREAST CANCER OUTCOMES. CHIEF SCIENTIFIC ADVISOR ANN PARTRIDGE, M.D., OF DANA-FARBER CANCER INSTITUTE, WILL INVESTIGATE UNIQUE BIOLOGICAL AND PSYCHOSOCIAL CHARACTERISTICS IN YOUNG WOMEN WITH BREAST CANCER. THE GOAL OF THIS RESEARCH IS TO IMPROVE TREATMENT OUTCOMES AND QUALITY OF LIFE FOR YOUNG WOMEN WITH BREAST CANCER WHO OFTEN EXPERIENCE GREATER DISTRESS THAN OLDER PATIENTS WITH BREAST CANCER. KOMEN SCHOLAR OLUFUNMILAYO OLOPADE, M.D., OF THE UNIVERSITY OF CHICAGO, WAS AWARDED A GRANT TO INVESTIGATE DIFFERENCES IN TREATMENT RESPONSE BETWEEN WHITE AND BLACK BREAST CANCER PATIENTS. BY PROVIDING A BETTER UNDERSTANDING OF HOW BLACK WOMEN'S TUMORS RESPOND TO TREATMENTS, THIS STUDY WILL HELP IMPROVE OUTCOMES IN THIS POPULATION. LEADERSHIP GRANTS - NEW KOMEN SCHOLARS: KOMEN SCHOLAR JEFFREY M. ROSEN, PH.D., OF BAYLOR COLLEGE OF MEDICINE, WILL STUDY HOW MACROPHAGES, A TYPE OF IMMUNE CELL, AFFECT TRIPLE NEGATIVE BREAST CANCER (TNBC). THE GOAL OF THIS STUDY IS TO IDENTIFY NEW MACROPHAGE-TARGETED IMMUNOTHERAPY DRUGS THAT COULD BE USED IN FUTURE CLINICAL TRIALS TO TREAT METASTATIC TNBC. KOMEN SCHOLAR BRYAN SCHNEIDER, M.D., OF INDIANA UNIVERSITY, WAS AWARDED A GRANT TO STUDY A TOXIC SIDE EFFECT FROM CHEMOTHERAPY THAT OCCURS MORE FREQUENTLY IN AFRICAN AMERICAN BREAST CANCER PATIENTS COMPARED TO OTHER POPULATIONS. THE GOAL OF THIS STUDY IS TO DECREASE THE DISPARITY IN SURVIVAL RATES FOR AFRICAN AMERICAN BREAST CANCER PATIENTS THROUGH PERSONALIZED MEDICINE. KOMEN SCHOLAR CARLOS ARTEAGA, M.D., OF THE UNIVERSITY OF TEXAS SOUTHWESTERN, WILL INVESTIGATE WHY SOME ER+ BREAST TUMORS BECOME RESISTANT TO CDK4/6 INHIBITORS. THE GOAL OF THIS STUDY IS TO CIRCUMVENT RESISTANCE TO THESE DRUGS TO IMPROVE OUTCOMES FOR PATIENTS WITH METASTATIC ER+ BREAST CANCER. KOMEN SCHOLAR MYLES BROWN, M.D., OF DANA-FARBER CANCER INSTITUTE, WILL STUDY HOW BREAST TUMORS FORM USING CUTTING-EDGE RNA SEQUENCING TECHNIQUES. THROUGH UNDERSTANDING THE FORMATION OF BREAST TUMORS, DR. BROWN HOPES TO UNCOVER NEW THERAPEUTIC TARGETS FOR BREAST CANCER PREVENTION KOMEN SCHOLAR SUSAN DOMCHEK, M.D., OF THE UNIVERSITY OF PENNSYLVANIA, WILL INVESTIGATE NEW STRATEGIES FOR HELPING WOMEN WITH BRCA1 AND BRCA2 MUTATIONS MAKE DECISIONS REGARDING BREAST CANCER SCREENING AND RISK-REDUCING SURGERY. THE GOAL OF THIS PROJECT IS TO CAPITALIZE ON NEW ADVANCES IN GENETIC TESTING TECHNOLOGY TO EMPOWER PATIENTS TO MAKE THE BEST DECISIONS FOR THEIR BREAST HEALTH. KOMEN SCHOLAR DAVID MANKOFF, M.D., PH.D., OF THE UNIVERSITY OF PENNSYLVANIA, WAS AWARDED FUNDS TO STUDY NEW APPLICATIONS OF PET MOLECULAR IMAGING IN BREAST CANCER. FROM THESE STUDIES, DR. MANKOFF EXPECTS TO IMPROVE DIAGNOSTIC CAPABILITIES FOR ALL BREAST CANCERS, BUT PARTICULARLY FOR THOSE DIFFICULT TO DETECT WITH CURRENT TECHNOLOGY, SUCH AS INVASIVE LOBULAR BREAST CANCER. KOMEN SCHOLAR HARIKRISHNA NAKSHATRI, PH.D., OF INDIANA UNIVERSITY, WILL STUDY A PROTEIN CALLED TONSL THAT IS ABNORMALLY INCREASED IN BREAST TUMORS AND LEADS TO RESISTANCE OF PARP INHIBITORS, THE TREATMENT OF CHOICE FOR PATIENTS WITH BRCA1/2 GENE MUTATIONS. THE GOAL OF THIS RESEARCH IS TO IDENTIFY DRUGS THAT TARGET TONSL THAT CAN BE USED IN PATIENTS WITH BRCA1/2 MUTATIONS WHOSE TUMORS DEVELOP RESISTANCE TO PARP INHIBITORS. KOMEN SCHOLAR KATHY MILLER, M.D., OF INDIANA UNIVERSITY, WILL CONDUCT A CLINICAL TRIAL THAT WILL TEST WHETHER BLACK WOMEN BENEFIT FROM A NEW DRUG COMBINATION DESIGNED TO DECREASE HEIGHTENED INFLAMMATION THAT IS OFTEN OBSERVED IN BREAST CANCER IN BLACK WOMEN. AS BLACK WOMEN ARE 40% MORE LIKELY TO DIE FROM BREAST CANCER THAN WHITE WOMEN, THIS TRIAL HAS THE POTENTIAL TO CLOSE THE GAP OF THIS DISPARITY AND IMPROVE THE POOR OUTCOMES THAT BLACK WOMEN FACE. KOMEN SCHOLAR, ANTONIO WOLFF, M.D., OF JOHNS HOPKINS UNIVERSITY, WILL CONDUCT A CLINICAL TRIAL EVALUATING THE OPTIMAL STRATEGY FOR TREATING TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS WITH IMMUNOTHERAPY. THE GOAL OF THIS RESEARCH IS TO ENSURE THAT PATIENTS WITH NEWLY DIAGNOSED TNBC RECEIVE IMMUNOTHERAPY AT THE RIGHT TIME, IN AN OPTIMIZED FASHION. MBC COLLABORATIVE RESEARCH INITIATIVE KATHERINE REEDER-HAYES, M.D., OF UNIVERSITY OF NORTH CAROLINA CHAPEL-HILL AND DEVON CHECK, PH.D., OF DUKE UNIVERSITY ARE COLLABORATING ON A RESEARCH STUDY AS PART OF THE MBC-COLLABORATIVE RESEARCH INITIATIVE. THEY WILL WORK TOGETHER TO INCREASE OUR UNDERSTANDING OF THE KEY SOCIAL DETERMINANTS OF HEALTH (SDOH) OF METASTATIC BREAST CANCER (MBC) DEVELOPMENT AND OUTCOMES THROUGH RECRUITING A DIVERSE GROUP OF WOMEN LIVING WITH MBC TO INVESTIGATE HOW CHRONIC STRESS, INFLAMMATION AND IMMUNE SYSTEM CHANGES IMPACT BLACK AND WHITE WOMEN WITH MBC TO IMPROVE PATIENT OUTCOMES. OPPORTUNITY GRANTS: ANTONIO WOLFF, M.D., OF JOHNS HOPKINS UNIVERSITY, WILL RECEIVE FUNDING TO SUPPORT THE TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM (TBCRC). THE TBCRC, A GROUP OF 19 CLINICAL SITES, PROVIDES A FORUM WHERE INVESTIGATORS, ADVOCATES, COORDINATORS, SCIENTISTS AND BIOSTATISTICIANS WORK TOGETHER TO PLAN AND REFINE CLINICAL TRIALS, ADVANCING BREAST CANCER KNOWLEDGE MORE EFFICIENTLY ACROSS THE FIELD. MORE THAN HALF OF TBCRC TRIALS HAVE FOCUSED ON METASTATIC BREAST CANCER. MELISSA TROESTER, PH.D., OF THE UNIVERSITY OF NORTH CAROLINA, WILL RECEIVE FUNDING TO CONTINUE THE CAROLINA BREAST CANCER STUDY, INTEGRATING CLINICAL, BIOLOGICAL, AND SOCIAL INFORMATION TO DETERMINE HOW DISPARITIES ARISE ACROSS MULTIPLE LEVELS, FROM THE BIOLOGY OF THEIR TUMORS TO THE FACTORS, THAT IMPACT THEIR CARE WITHIN THEIR COMMUNITIES. THESE STUDIES WILL IDENTIFY INTERVENTIONS THAT IMPROVE OUTCOMES AND CLOSE THE RACIAL GAP IN BREAST CANCER SURVIVAL FOR BLACK WOMEN.
Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	MICHELE COTE, PH.D., OF INDIANA UNIVERSITY (IU), WILL RECEIVE FUNDING TO SUPPORT A PARTNERSHIP BETWEEN THE SUSAN G. KOMEN TISSUE BANK (KTB) AND KOMEN'S BIG DATA FOR BREAST CANCER (BD4BC) INITIATIVE, A PROGRAM DESIGNED TO EXPLORE THE POWER OF BIG DATA FOR ADVANCING RESEARCH AND IMPROVING BREAST CANCER PATIENT CARE AND OUTCOMES. THIS GRANT WILL SUPPORT THE COLLECTION AND STORAGE OF SALIVA FOR PATIENT-DRIVEN RESEARCH. EDUCATION KOMEN IS A TRUSTED SOURCE OF BREAST CANCER INFORMATION FOR PEOPLE ALL OVER THE WORLD AND IS INSTRUMENTAL IN CONNECTING PEOPLE WITH THE RESOURCES THEY NEED IN THEIR FIGHT AGAINST BREAST CANCER. OUR WEBSITE, KOMEN.ORG, PROVIDES CURRENT, SAFE, ACCURATE, COMPREHENSIVE, AND UNBIASED INFORMATION ABOUT BREAST CANCER, BASED ON SCIENTIFIC EVIDENCE. CONTENT IS OFFERED IN A VARIETY OF FORMATS INCLUDING INTERACTIVE VIDEO USING ANIMATION AND VOICEOVER IN ENGLISH AND SPANISH, ILLUSTRATIONS, CHARTS, GRAPHS, AND SHORT VIDEOS TO MEET THE LEARNING PREFERENCES AND NEEDS OF OUR WEB VISITORS. THE ABOUT BREAST CANCER AND PORTIONS OF THE PATIENT & CAREGIVER SECTIONS OF KOMEN'S WEBSITE, CO-DEVELOPED WITH HARVARD MEDICAL SCHOOL FACULTY AND DANA-FARBER CANCER INSTITUTE STAFF, RECEIVED MORE THAN 3 MILLION PAGE VIEWS DURING FY23. KOMEN USED THE CLINICAL TRIALS INITIATIVE ON KOMEN.ORG TO EDUCATE PEOPLE ABOUT THE ROLE CLINICAL TRIALS, INCLUDING THOSE FROM UNDER- REPRESENTED POPULATIONS, AND EMPOWERING PEOPLE WITH INFORMATION ON TRIALS AND RESOURCES, WITH PERSONALIZED SUPPORT AVAILABLE THROUGH THE KOMEN BREAST CARE HELPLINE. THE RESOURCES HELP TO ENSURE PATIENTS ARE EQUIPPED TO MAKE INFORMED DECISIONS REGARDING TRIAL PARTICIPATION IN PARTNERSHIP WITH THEIR HEALTH CARE PROVIDERS. THE INITIATIVE ALSO RAISES AWARENESS OF THE DIFFERENT TYPES OF TRIALS, INCLUDING TRIALS SUPPORTED BY KOMEN, FOCUSED ON RISK, SCREENING AND EARLY DETECTION, TREATMENT, FAMILY SUPPORT, QUALITY OF LIFE AND SURVIVORSHIP. KOMEN ALSO PROVIDES EVIDENCE-BASED, EASY-TO-READ EDUCATIONAL MATERIALS IN DOWNLOADABLE FORMATS ON KOMEN.ORG. EXAMPLES OF KOMEN EDUCATIONAL MATERIALS INCLUDE: A) BREAST SELF-AWARENESS MESSAGE CARDS IN MORE THAN 40 LANGUAGES, B) BREAST CANCER SPECIFIC BROCHURES AND FACT SHEETS, AND C) BOOKLETS WITH SUPPORT INFORMATION FOR SURVIVORS AND CO-SURVIVORS. IN ADDITION, IN FY23 KOMEN CONTINUED TO SUPPORT THE METASTATIC BREAST CANCER (MBC) COMMUNITY BY HOSTING 12 VIRTUAL EVENTS THROUGH THE MBC IMPACT SERIES. THESE EVENTS PROVIDED PEOPLE LIVING WITH METASTATIC BREAST CANCER AND THEIR LOVED ONES A SAFE, COLLABORATIVE SPACE TO GATHER INFORMATION AND DISCOVER PRACTICAL RESOURCES TO HELP MAKE DECISIONS FOR IMPROVED PHYSICAL AND EMOTIONAL HEALTH. WE OFFER ON-DEMAND VIDEOS OF THESE EVENTS IN BOTH ENGLISH AND SPANISH FOR THOSE NOT ABLE TO ATTEND LIVE. THE MBC IMPACT SERIES ALSO OFFERS REGULAR NEWSLETTERS AND QUARTERLY WELLNESS WEDNESDAY VIDEOS FOCUSED ON QUALITY OF LIFE AND OVERALL WELLNESS TOPICS. PATIENT SUPPORT WIDESPREAD BARRIERS TO CARE CONTRIBUTE TO POOR OUTCOMES AND DEATH FROM BREAST CANCER. THESE BARRIERS INCLUDE SOCIOECONOMIC FACTORS, A LACK OF ACCESS TO CARE AND INFORMATION, AND DISCRIMINATION IN HEALTH CARE AND QUALITY OF CARE. SUSAN G. KOMEN'S PATIENT CARE CENTER (PCC) PROVIDES INDIVIDUALIZED CARE TO HELP ENSURE THE BEST POSSIBLE OUTCOMES FOR EVERY PERSON IN NEED OF SUPPORT THROUGHOUT THEIR BREAST CANCER JOURNEY. OUR TEAM OF CULTURALLY RESPONSIVE NAVIGATORS PROVIDED MORE THAN 42,000 SERVICES TO OVER 30,000 PEOPLE THIS YEAR, INCLUDING: * ANSWERS TO QUESTIONS ABOUT BREAST CANCER RISK. * EMOTIONAL SUPPORT AND GUIDANCE IN ADDRESSING FEELINGS AND OTHER CONCERNS. * INFORMATION ABOUT BREAST CANCER SCREENING, TREATMENT OPTIONS, CLINICAL TRIALS, SUPPORT RESOURCES, AND GENETIC COUNSELING AND TESTING. * ACCESS TO NO-COST SCREENING MAMMOGRAMS AND DIAGNOSTIC SERVICES BASED ON INCOME ELIGIBILITY. * FINANCIAL ASSISTANCE FOR INCOME-ELIGIBLE BREAST CANCER PATIENTS IN TREATMENT OR LIVING WITH METASTATIC BREAST CANCER. * NAVIGATING THE HEALTH CARE SYSTEM, INCLUDING COMMUNICATING WITH HEALTH CARE PROVIDERS, UNDERSTANDING TREATMENT OPTIONS AND ACCESSING SUPPORT SERVICES. THE KOMEN PCC TEAM IS MADE UP OF MORE THAN 50 HIGHLY SKILLED PROFESSIONALS WHO ARE AS DIVERSE AS THOSE WE SERVE . OUR CARING AND COMPASSIONATE TEAM INCLUDES ONCOLOGY SOCIAL WORKERS, BILINGUAL SPECIALISTS, SUBJECT MATTER EXPERTS AND BREAST CANCER SURVIVORS FROM AROUND THE COUNTRY WHO UNDERSTAND THAT EVERYONE'S HEALTH CARE JOURNEY IS UNIQUE, THUS PROVIDING INDIVIDUALIZED CARE TO ENSURE THE BEST POSSIBLE OUTCOMES FOR EACH PERSON. METASTATIC BREAST CANCER COLLABORATIVE RESEARCH INITIATIVE KOMEN LAUNCHED THE METASTATIC BREAST CANCER COLLABORATIVE RESEARCH INITIATIVE (MBCCRI) WITH A PILOT PROGRAM AT DUKE UNIVERSITY AND THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL. THE GOAL IS TO CATALYZE AND SUPPORT MULTI-INSTITUTIONAL RESEARCH COLLABORATIONS AND BRING TOGETHER THE BEST AND BRIGHTEST RESEARCHERS AT SELECT INSTITUTIONS TO SHARE IDEAS, EXPERTISE AND RESOURCES. KOMEN WILL SUPPORT RESEARCH GRANT TO FIND BREAKTHROUGH DISCOVERIES TO END METASTATIC BREAST CANCER. INFLAMMATORY BREAST CANCER COLLABORATIVE FOR THE FIRST TIME, KOMEN IS LEADING TO DRIVE A NEW DIAGNOSTIC DEFINITION OF BREAST CANCER, SPECIFICALLY INFLAMMATORY BREAST CANCER, A DEADLY AND AGGRESSIVE FORM OF CANCER. KOMEN HAS PARTNERED WITH THE INFLAMMATORY BREAST CANCER RESEARCH FOUNDATION AND THE MILBURN FOUNDATION TO CONVENE PATIENT ADVOCATES, BREAST CANCER RESEARCHERS AND CLINICIANS TO REVIEW THE STATE OF IBC CARE AND RESEARCH GLOBALLY AND PROPOSE SPECIFIC INITIATIVES TO MOVE THE FIELD FORWARD. THE OUTCOME OF THE DISCUSSIONS WAS ABUNDANTLY CLEAR: THE FIELD NEEDS A FORMAL DEFINITION OF IBC. WITHOUT A CLEAR DEFINITION, BOTH PATIENT CARE AND RESEARCH SUFFER. DIAGNOSIS REMAINS SUBJECTIVE AND TREATMENT VARIABLE. THE GOAL IS TO MOVE BEYOND THE SUBJECTIVE 'CLINICAL DIAGNOSIS' TO A SET OF SPECIFIC DIAGNOSTIC CRITERIA AND SCORING SYSTEM THAT WILL ADVANCE IBC RESEARCH AND FACILITATE THE DISCOVERIES THAT WILL IMPROVE CARE OF IBC PATIENTS. A PROPOSED DEFINITION OF IBC, BASED ON A REVIEW OF CLINICAL, AND PATHOLOGIC FEATURES IS BEING VALIDATED. BIG DATA FOR BREAST CANCER KOMEN CONTINUES WORK ON THE BIG DATA FOR BREAST CANCER INITIATIVE, WHICH IS AIMED AT USING BIG DATA TO FUEL SCIENTIFIC DISCOVERIES AND ACCELERATE THE DELIVERY OF EQUITABLE, PATIENT-FOCUSED CARE. KOMEN EMPOWERS BREAST CANCER PATIENTS, ADVOCATES AND THE PUBLIC WITH INFORMATION AND TOOLS TO MAKE DATA SHARING UNDERSTANDABLE THROUGH THE BIG DATA FOR PATIENTS EDUCATIONAL PROGRAMS. WE ALSO ADDRESS THE CHALLENGES OF INCORPORATING BIG DATA APPLICATIONS INTO BREAST CANCER RESEARCH AND CLINICAL CARE THROUGH WORKING WITH PARTNERS REPRESENTING A VARIETY OF STAKEHOLDERS IN BREAST CANCER RESEARCH AND CLINICAL CARE. ADDITIONALLY, KOMEN SUPPORTS DATA SCIENCE PROJECTS TO IMPROVE BREAST CANCER OUTCOMES AND SAVE LIVES. PUBLIC POLICY AND ADVOCACY SUSAN G. KOMEN IS THE NONPARTISAN VOICE OF MORE THAN 4 MILLION BREAST CANCER SURVIVORS AND THOSE LIVING WITH THE DISEASE IN THE U.S. AS WELL AS THE PEOPLE WHO LOVE THEM. KOMEN WORKS TO EDUCATE PEOPLE ABOUT PUBLIC POLICY ISSUES SO THEY ARE EMPOWERED TO BECOME FORCEFUL ADVOCATES FOR THEMSELVES AND THEIR NEIGHBORS AND THEN UNITES THEIR COLLECTIVE VOICES FOR MAXIMUM IMPACT. THE CENTER FOR PUBLIC POLICY IS THE CORNERSTONE OF KOMEN'S MISSION, TO END BREAST CANCER FOREVER, THROUGH SOUND PUBLIC POLICY AND ADVOCACY COUPLED WITH SCIENTIFIC PROGRESS AND PATIENT SUPPORT SERVICES DESIGNED TO OVERCOME BARRIERS TO CARE. THE CENTER FOR PUBLIC POLICY IS THE DRIVING FORCE THAT ENSURES THE VOICE OF BREAST CANCER PATIENTS, SCIENTISTS, HEALTH CARE PROFESSIONALS, CAREGIVERS, AND ENGAGED MEMBERS OF THE PUBLIC WILL BE HEARD BY GOVERNMENT REGULATORS ON LOCAL, STATE AND NATIONAL LEVELS. KOMEN BELIEVES THAT ONLY THROUGH INFORMED GOVERNMENT ACTION CAN BROAD, SYSTEMIC AND LASTING CHANGES BE MADE TO PROTECT BREAST CANCER PATIENTS.
Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	KOMEN'S 2022-2023 PUBLIC POLICY AND ADVOCACY PRIORITIES INCLUDED: EXPANDING ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL PATIENT POPULATIONS; SUPPORTING INCREASED STATE AND FEDERAL FUNDING FOR BREAST CANCER RESEARCH AND INCREASED EDUCATION, UTLIZATION OF AND ACCESS TO CLINICAL TRIALS; SUPPORTING STATE AND FEDERAL FUNDING FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S (CDC) NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM (NBCCEDP); ADVOCATING FOR STATE AND FEDERAL POLICIES TO IMPROVE INSURANCE COVERAGE OF BREAST CANCER TREATMENTS, INCLUDING THOSE THAT WOULD REQUIRE ORAL PARITY, PRECLUDE SPECIALTY TIERS AND PREVENT STEP THERAPY PROTOCOLS; AND ADVOCATING FOR STATE AND FEDERAL POLICIES TO REDUCE OR ELIMINATE OUT-OF-POCKET COSTS FOR MEDICALLY NECESSARY DIAGNOSTIC IMAGING. IN ADDITION TO THE STATE AND FEDERAL WORK ON OUR PUBLIC POLICY AND ADVOCACY PRIORITIES, KOMEN ALSO ENGAGED ON ISSUES RELATED TO CUSTOM BREAST PROTHESES, GENETIC AND GENOMIC TESTING, LYMPHEDEMA, MEDICARE WAITING PERIODS, PALLIATIVE CARE, SURPRISE MEDICAL BILLING AND SURVIVORSHIP. KOMEN DEVELOPED AND IMPLEMENTED ADVOCACY CAMPAIGNS TO ENCOURAGE LAWMAKERS AND AGENCY OFFICIALS TO SUPPORT AND IMPLEMENT PROGRAMS THAT WOULD ADVANCE OUR PRIORITY ISSUES. KOMEN CONTINUED TO RECRUIT AND ENGAGE ADVOCATES TO FURTHER STRENGTHEN ITS GRASSROOTS ADVOCACY NETWORK.
Form 990, Part VI, Line 1a Executive Committee	THE ORGANIZATION'S BYLAWS PROVIDE FOR AN EXECUTIVE COMMITTEE COMPRISED OF A MINIMUM OF FIVE MEMBERS INCLUDING THE BOARD CHAIR, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND ADDITIONAL BOARD MEMBERS, AS RECOMMENDED BY THE GOVERNANCE COMMITTEE AND APPOINTED BY THE BOARD OF DIRECTORS. MEMBERS OF THE EXECUTIVE COMMITTEE MUST EITHER BE DIRECTORS OF THE ORGANIZATION OR THE PRESIDENT AND CHIEF EXECUTIVE OFFICER. THE BYLAWS PROVIDE THE EXECUTIVE COMMITTEE WITH THE AUTHORITY TO: (A) APPOINT MEMBERS TO NON-STANDING COMMITTEES OF THE ORGANIZATION, AND NAME CHAIRS OF SUCH COMMITTEES; (B) AUTHORIZE UNBUDGETED DISBURSEMENTS BY THE ORGANIZATION IN ACCORDANCE WITH THE SPECIFIC EXPENDITURE AUTHORITY PRESCRIBED BY THE BOARD OF DIRECTORS; (C) EMPLOY AGENTS; AND (D) CARRY INTO EXECUTION SUCH OTHER MEASURES AS IT DETERMINES WILL PROMOTE THE PURPOSE OF THE ORGANIZATION. THE COMMITTEE ALSO MAY EXERCISE, WHEN THE BOARD IS NOT IN SESSION, ALL OF THE AUTHORITY OF THE BOARD IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE ORGANIZATION WITH CERTAIN EXCEPTIONS SUCH AS REPEALING ANY BOARD RESOLUTIONS, AMENDING THE ORGANIZATION'S ARTICLES OR BYLAWS, OR MERGING OR DISSOLVING THE ORGANIZATION. THIS DELEGATION DOES NOT RELIEVE THE BOARD OF ANY OF ITS RESPONSIBILITIES IMPOSED BY LAW, AND THE COMMITTEE ENDEAVORS TO LIMIT ITS EXERCISE OF AUTHORITY TO TIME SENSITIVE ISSUES.
Form 990, Part VI, Line 11b Review of form 990 by governing body	MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE OF AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVEL MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR SUBSEQUENT PRESENTATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWS, MAKES RECOMMENDATIONS, AND APPROVES THE FORM 990 FOR PRESENTATION TO THE BOARD OF DIRECTORS. THEREAFTER, THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE FORM 990 PRIOR TO FILING.
Form 990, Part VI, Line 12c Conflict of interest policy	KOMEN'S CONFLICT OF INTEREST POLICY REQUIRES EVERY BOARD MEMBER, OFFICER, DIRECTOR, COMMITTEE MEMBER, ADVISORY BOARD MEMBER, EMPLOYEE, AND VOLUNTEER TO AVOID CONFLICTS OF INTEREST. IT ALSO REQUIRES THESE PERSONS TO REPORT ANY ACTUAL AND/OR POTENTIAL CONFLICTS OF INTEREST AS SOON AS POSSIBLE. REPORTS ARE REVIEWED BY THE GENERAL COUNSEL'S OFFICE AND/OR INTERNAL AUDIT, AND APPROPRIATE ACTION IS TAKEN PURSUANT TO THE CONFLICT OF INTEREST POLICY. FURTHER, KOMEN REQUIRES ALL BOARD MEMBERS, OFFICERS, DIRECTORS, COMMITTEE MEMBERS, ADVISORY BOARD MEMBERS, AND EMPLOYEES TO REVIEW AND EXECUTE THE CONFLICT OF INTEREST POLICY ANNUALLY AND DISCLOSE ANY ADDITIONAL ACTUAL/POTENTIAL CONFLICTS OF INTEREST. THESE ANNUAL DISCLOSURES ARE REVIEWED IN THE SAME MANNER. THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS RECEIVES, AND REVIEWS ALL REPORTED ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AND THE RELATED ACTION TO ADDRESS THEM.
Form 990, Part VI, Line 15a Process to establish compensation of top management official	THE HUMAN CAPITAL MANAGEMENT COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2023, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION.
Form 990, Part VI, Line 15b Process to establish compensation of other employees	THE HUMAN CAPITAL MANAGEMENT COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2023, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION.
Form 990, Part VI, Line 19 Required documents available to the public	KOMEN'S FINANCIAL STATEMENTS AND THE FORM 990 ARE PUBLICLY AVAILABLE ON OUR WEBSITE. THE CERTIFICATE OF FORMATION IS AVAILABLE FROM THE TEXAS SECRETARY OF STATE AND OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE AS REQUIRED BY STATE LAW. FORM 1023 AND THE CONFLICT OF INTEREST POLICY ARE NOT PUBLISHED ONLINE BUT ARE AVAILABLE TO THE PUBLIC UPON REQUEST.
Form 990, Part IX, Line 1	FOR NEARLY 40 YEARS, SUSAN G. KOMEN HAS WORKED TO FULFILL ITS VISION OF CREATING A WORLD WITHOUT BREAST CANCER THROUGH ITS MISSION OF SAVING LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAKTHROUGH RESEARCH TO BETTER DETECT, PREVENT, TREAT BREAST CANCERS. OVER THE LAST THREE YEARS, KOMEN CONTINUED TO IMPLEMENT A SERIES OF CHANGES BEGUN IN 2020 TO STRENGTHEN ITS FINANCIAL AND OPERATIONAL POSITION IN RESPONSE TO THE CHANGING NEEDS OF THE BREAST CANCER COMMUNITY AND ECONOMIC CONDITIONS RESULTING FROM THE COVID-19 PANDEMIC. KOMEN HAS NEARLY COMPLETED THE CONSOLIDATION OF ALL OPERATIONS OF ITS INDEPENDENT AFFILIATES INTO ITS HEADQUARTERS ORGANIZATION, RESULTING IN A SINGLE ORGANIZATION. THIS CONSOLIDATION IS ENABLING KOMEN TO LEVERAGE THE COMBINED EXPERTISE OF ITS MISSION LEADERS TO DELIVER A UNITED MISSION PROGRAM, UTILIZING TECHNOLOGY AS A KEY DRIVER TO CONNECT TO PEOPLE WHO NEED TO ACCESS CARE WHERE THEY ARE AND TO HELP IMPROVE THE PATIENT EXPERIENCE, AS WELL AS RESULTED IN ADMINISTRATIVE AND OPERATIONAL EFFICIENCIES. CENTRAL TO KOMEN'S VISION IS A STEADFAST COMMITMENT TO INVESTING IN BREAKTHROUGH RESEARCH. KOMEN REMAINED COMMITTED TO INVESTING IN RESEARCH CENTERED ON THE PRIMARY FOCUS OF METASTATIC BREAST CANCER AND UNDERSTANDING AND ELIMINATING DISAPARITIES IN BREAST CANCER OUTCOMES BETWEEN BLACK AND WHITE PATIENTS. DESPITE THE ECONOMIC UNCERTAINTY AND CHALLENGING FUNDRAISING ENVIRONMENT, KOMEN AWARDED $40 MILLION IN NEW RESEARCH AWARDS OVER THE PAST TWO FISCAL YEARS. WHILE WE CONTINUE TO INVEST IN RESEARCH INTO NEW TREATMENTS, KOMEN SUPPORTS PEOPLE WHO ARE FACING BREAST CANCER TODAY THROUGH A GROWING SUITE OF PATIENT CARE SERVICES, INCLUDING DIRECT FINANCIAL ASSISTANCE THROUGH ITS TREATMENT ASSISTANCE PROGRAM, ELIGIBLE TO HELP PAY FOR EXPENSES THAT MAY SERVE AS A BARRIER TO ATTAINING THE CARE NEEDED TO SURVIVE, SUCH AS CO-PAYS, TRANSPORTATION, CHILDCARE OR RENT.
Form 990, Part XI, Line 9 Other changes in net assets or fund balances	RESCINDED GRANTS - 1101560; Program COGS - -32562;